var title_f11_24_11648="Inflammatory diarrhea child";
var content_f11_24_11648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 612px\">",
"   <div class=\"ttl\">",
"    Algorithm for evaluation of a child with inflammatory diarrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 592px; height: 497px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This algorithm shows a typical diagnostic pathway for many patients in this age group. Other sequences of testing may be appropriate in some cases.",
"    <div class=\"footnotes\">",
"     CT: computerized tomography; MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11648=[""].join("\n");
var outline_f11_24_11648=null;
var title_f11_24_11649="WBC differential Advia2120";
var content_f11_24_11649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    WBC differential Advia 2120",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A white cell differential on the Advia 2120 automated cell counter is shown here. Staining for peroxidase (perox) is displayed on the x axis versus cell size on the y axis. Neutrophils (pink) and eosinophils (yellow) containing the most perox activity are found to the right. Cells with little or no perox cluster to the left, such as lymphocytes/basophils (blue) and large unstained cells (blasts, variant and atypical lymphocytes, light blue). Monocytes (green) contain a small amount of perox and are located between the neutrophils and large unstained cells. Noise is indicated in the lower left hand corner (white). Nucleated red blood cells are present in the area between lymphocytes and noise; platelet clumps are found in the area to the right of the nucleated red blood cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11649=[""].join("\n");
var outline_f11_24_11649=null;
var title_f11_24_11650="Patient information: Mumps (The Basics)";
var content_f11_24_11650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82905\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/53/34655\">",
"         A child with mumps",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/14/5346\">",
"         Patient information: Parotitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/36/42566\">",
"         Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/42/18084\">",
"         Patient information: Why does my child need vaccines? (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Mumps (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/mumps-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H24836420\">",
"      <span class=\"h1\">",
"       What is mumps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Mumps is an infection caused by a virus. It causes swelling of the glands in front of the ears and above the jaw (",
"      <a class=\"graphic graphic_picture graphicRef82766 \" href=\"UTD.htm?33/53/34655\">",
"       picture 1",
"      </a>",
"      ). These glands are called &ldquo;parotid&rdquo; glands.",
"     </p>",
"     <p>",
"      Mumps used to be much more common than it is now. Few people get mumps now because most children get a vaccine that helps prevent the infection. It is called the MMR vaccine. The MMR vaccine combines vaccines for mumps and 2 other infections (measles and rubella) in one shot. Doctors recommend that all children get the MMR vaccine as part of their routine childhood vaccines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24836435\">",
"      <span class=\"h1\">",
"       What are the symptoms of mumps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people have no symptoms. But in most people, the early symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Feeling tired and achy",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Poor appetite",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      About 2 days after the early symptoms start, the parotid glands become swollen. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24836450\">",
"      <span class=\"h1\">",
"       How does mumps spread?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have not had mumps or had the MMR vaccine, you can catch mumps just by being around someone who is infected. After you catch the infection, symptoms start in about 14 to 18 days.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24836467\">",
"      <span class=\"h1\">",
"       Should I go to the doctor or nurse if I think my child or I have mumps?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Do not go to the doctor or nurse without calling first. Your doctor or nurse might be able to tell you what to do over the phone. That way you will not risk infecting other people at the doctor&rsquo;s office.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24836482\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help your symptoms, your doctor or nurse might recommend that you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Put heat on the swollen area. Wet a clean wash cloth with warm water and put it on the area. When the wash cloth cools, reheat it with warm water and put it back on. Repeat these steps for 10 to 15 minutes every few hours.",
"       </li>",
"       <li>",
"        Take over-the-counter medicines such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil, Motrin). These medicines help ease pain and fever. Adults can also take",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        for pain and fever. But NEVER give aspirin for fever to a child or teenager who is younger than 18 years old. In children and teens, aspirin can cause a dangerous condition called Reye syndrome.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24836497\">",
"      <span class=\"h1\">",
"       When will I feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with mumps usually get better in about 2 weeks. In rare cases, mumps can cause other problems, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling of one or both testicles in boys and men",
"       </li>",
"       <li>",
"        Inflammation of the ovaries in girls and women",
"       </li>",
"       <li>",
"        Infections in and around the brain",
"       </li>",
"       <li>",
"        Deafness",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24836512\">",
"      <span class=\"h1\">",
"       Does the MMR vaccine cause autism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. After doing many careful studies, scientists have not found any link between the MMR vaccine and autism. Many years ago, one study found a link between autism and the MMR vaccine. But that study turned out to be false.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24836529\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/14/5346?source=see_link\">",
"       Patient information: Parotitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       Patient information: Why does my child need vaccines? (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/24/11650?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82905 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11650=[""].join("\n");
var outline_f11_24_11650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24836420\">",
"      What is mumps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24836435\">",
"      What are the symptoms of mumps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24836450\">",
"      How does mumps spread?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24836467\">",
"      Should I go to the doctor or nurse if I think my child or I have mumps?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24836482\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24836497\">",
"      When will I feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24836512\">",
"      Does the MMR vaccine cause autism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24836529\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82905\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/53/34655\">",
"      A child with mumps",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/14/5346?source=related_link\">",
"      Patient information: Parotitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_24_11651="Mandibular gingivitis";
var content_f11_24_11651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mandibular gingivitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Heavy plaque accumulations and gingivitis with papillary edema and marginal erythema can be seen on the mandibular teeth of this child with orthodontic appliances. Oral hygiene has been better on the maxillary anterior teeth, and the gingiva appears healthy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ann Griffen, DDS, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11651=[""].join("\n");
var outline_f11_24_11651=null;
var title_f11_24_11652="Psoas compartment block";
var content_f11_24_11652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Psoas compartment block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 616px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For psoas compartment block the needle insertion site can be localized in one of two ways:",
"    <ul>",
"     <li>",
"      In method 1, the needle is inserted 4 cm lateral to the midline along a line drawn from the iliac crest to the L4&nbsp;spinous processes in the midline of the back.",
"     </li>",
"     <li>",
"      In method 2, the needle insertion site is found by first drawing a line (line 1) connecting the iliac crests. The posterior superior iliac spine (PSIS) is identified and the lumbar spinous processes are marked. A second line (line 2) is drawn through the PSIS parallel to a third line (line 3) connecting the spinous processes. The needle is inserted 1 cm cephalad to the junction of the lateral third and medial two-thirds of a line between the lines 2 and 3 at the level of L4.",
"     </li>",
"    </ul>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11652=[""].join("\n");
var outline_f11_24_11652=null;
var title_f11_24_11653="Fluorouracil (systemic): Patient drug information";
var content_f11_24_11653=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluorouracil (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10921?source=see_link\">",
"     see \"Fluorouracil (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/10/1190?source=see_link\">",
"     see \"Fluorouracil (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8100806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adrucil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluorouracil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bone marrow disease, dihydropyrimidine dehydrogenase deficiency, low blood cell count, surgery in the past month, or a very bad infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698464",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked to help avoid side effects. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, no period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May not be able to get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11684 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11653=[""].join("\n");
var outline_f11_24_11653=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100806\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027512\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027514\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027513\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027518\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027519\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027521\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027516\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027523\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10921?source=related_link\">",
"      Fluorouracil (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/10/1190?source=related_link\">",
"      Fluorouracil (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/58/13221?source=related_link\">",
"      Fluorouracil (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41396?source=related_link\">",
"      Fluorouracil (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/52/29508?source=related_link\">",
"      Fluorouracil (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_24_11654="Tolvaptan: Drug information";
var content_f11_24_11654=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tolvaptan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/62/19429?source=see_link\">",
"    see \"Tolvaptan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16055924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Tolvaptan and Potential Risk of Liver Injury",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) and Otsuka Pharmaceuticals have notified healthcare providers that findings of a double-blind, placebo controlled trial (n=1445) and its open-label extension trial indicate that treatment with tolvaptan may have resulted in a significant increase in serum alanine aminotransferase (ALT) and serum total bilirubin in three patients with autosomal dominant polycystic kidney disease (ADPKD). Hepatic effects were noted during the first 18 months of therapy and resolved upon discontinuation of tolvaptan therapy; doses used in the trial (120 mg/day) were higher than the maximum daily dose (60 mg/day) currently recommended for its FDA-approved use of hyponatremia. As a result, the FDA, in conjunction with Otsuka Pharmaceuticals, is warning healthcare providers that tolvaptan therapy has the potential to cause irreversible and potentially fatal liver injury.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Clinicians are advised to perform hepatic function tests in patients who develop symptoms consistent with liver injury (eg, fatigue, anorexia, right upper quadrant pain, dark urine, jaundice). If hepatic injury is suspected, discontinue tolvaptan, treat as clinically indicated, and determine the probable cause. Tolvaptan treatment should not be resumed unless the cause for the liver injury is definitively established to be unrelated to tolvaptan.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm336669.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm336669.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7810723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7794510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Samsca&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13276923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Samsca&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7810547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vasopressin Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7810606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hyponatremia:",
"     </b>",
"     Oral: Initial: 15 mg once daily; after at least 24 hours, may increase to 30 mg once daily to a maximum of 60 mg once daily titrating at 24-hour intervals to desired serum sodium concentration.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7810607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13797229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Use not recommended (not studied); contraindicated in anuria (no benefit expected).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13797228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7810612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Samsca&trade;: 15 mg, 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13276924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Samsca&trade;: 15 mg, 30 mg, 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7810545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11213964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM235540.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM235540.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7810608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment should be initiated or reinitiated in a hospital. May be administered without regards to meals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Nasogastric (NG) tube: Administration via NG tube resulted in an ~25% reduction in AUC and a modest reduction in C",
"     <sub>",
"      max",
"     </sub>",
"     in one study; 24-hour urine output was reduced by only 2.8%. Therefore, until further studies are done to determine a bioequivalent dose when administering via NG tube, NG tube administration of a crushed 15 mg tablet appears to be a viable alternative method of administration (McNeely, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7810548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of clinically significant hypervolemic or euvolemic hyponatremia (associated with heart failure, cirrhosis, or SIADH) with either a serum sodium &lt;125 mEq/L or less marked hyponatremia that is symptomatic and resistant to fluid restriction",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7810564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (21%), xerostomia (7% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Pollakiuria (4% to 11%), polyuria (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Thirst (12% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (6%), hypernatremia (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: GI bleeding (cirrhosis patients 10%), constipation (7%), anorexia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): ALT increased, bilirubin increased, cerebrovascular accident, deep vein thrombosis, diabetic ketoacidosis, disseminated intravascular coagulation, intracardiac thrombus, ischemic colitis, osmotic demyelination syndrome, prothrombin time prolonged, pulmonary embolism, respiratory failure, rhabdomyolysis, urethral hemorrhage, vaginal hemorrhage, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7810553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypovolemic hyponatremia; urgent need to raise serum sodium acutely; use in patients unable to sense or appropriately respond to thirst; anuria; concurrent use with strong CYP3A inhibitors (eg, ketoconazole, itraconazole, ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, telithromycin, clarithromycin)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to tolvaptan or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7810554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypovolemia/dehydration: Patients should ingest fluids in response to thirst during therapy. Interrupt or discontinue therapy in patients who develop significant signs or symptoms of hypovolemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serum sodium monitoring/initiating in hospital:",
"     <b>",
"      [U.S. Boxed Warning]: Tolvaptan should be initiated and reinitiated in patients only in a hospital where serum sodium can be closely monitored.",
"     </b>",
"     Too rapid correction of hyponatremia (ie, &gt;12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. In susceptible patients (including those with severe malnutrition, alcoholism, or advanced liver disease), slower rates of correction may be advisable. Patients with SIADH or very low baseline serum sodium concentrations may be at greater risk of overly-rapid correction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cirrhosis: Gastrointestinal bleeding can occur in patients with cirrhosis; use only if the need to treat outweighs the risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Reductions in extracellular fluid volumes may cause hyperkalemia. Patients with a pretreatment serum potassium &gt;5 mEq/L should be monitored after initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use in patients with creatinine clearance &lt;10 mL/minute has not been studied. Use is contraindicated in anuric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertonic saline: Use with hypertonic saline is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use contraindicated in patients taking strong CYP3A inhibitors; avoid use in patients taking moderate CYP3A4 inhibitors. If possible, avoid use with CYP3A4 inducers; if administered with CYP3A4 inducers, dose increases may be necessary. Dose reductions may be necessary if administered with P-gp inhibitors. Consider alternative agents that avoid or lessen the potential for CYP- or P-gp mediated interactions. Patients receiving medications known to increase potassium should be monitored for hyperkalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Monitor closely for rate of serum sodium increase and neurological status; rapid serum sodium correction (&gt;12 mEq/L/24 hours) can lead to permanent neurological damage. Discontinue use if rate of serum sodium increase is undesirable; fluid restriction during the first 24 hours of sodium correction can increase the risk of overly-rapid correction and should generally be avoided; not intended for urgent correction of serum sodium to prevent or treat serious neurologic symptoms; it has not been demonstrated that raising serum sodium with tolvaptan provides a symptomatic benefit.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7832267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Tolvaptan may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Tolvaptan may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Tolvaptan. Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Tolvaptan may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Tolvaptan may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Chloride: May enhance the adverse/toxic effect of Tolvaptan. Specifically, Hypertonic Saline may increase the risk for too rapid of an increase in serum sodium concentrations. Management: This interaction is specific to Hypertonic Saline.  Avoid concurrent use of Hypertonic Saline with Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7810568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Tolvaptan exposure may be doubled when taken with grapefruit juice. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease tolvaptan serum concentrations. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7810549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7810550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7810552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7810581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regards to meals. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Samsca Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (10): $3440.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (10): $3440.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7810610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum sodium concentration, rate of serum sodium increase, serum potassium concentration (if &gt;5 mEq/L prior to administration or receiving medications known to elevate serum potassium); volume status",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Samsca (CZ, DE, DK, EE, FR, GB, NL, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7810582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An arginine vasopressin (AVP) receptor antagonist with affinity for AVP receptor subtypes V",
"     <sub>",
"      2",
"     </sub>",
"     and V",
"     <sub>",
"      1a",
"     </sub>",
"     in a ratio of 29:1. Antagonism of the V",
"     <sub>",
"      2",
"     </sub>",
"     receptor by tolvaptan promotes the excretion of free water (without loss of serum electrolytes) resulting in net fluid loss, increased urine output, decreased urine osmolality, and subsequent restoration of normal serum sodium levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7810571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 60% peak serum sodium elevation is retained at 24 hours; urinary excretion of free water is no longer elevated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 5-12 hours; dominant half-life &lt;12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ali F, Guglin M, Vaitkevicus P, et al, &ldquo;Therapeutic Potential of Vasopressin Receptor Antagonists,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2007, 67(6):847-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11654/abstract-text/17428103/pubmed\" id=\"17428103\" target=\"_blank\">",
"        17428103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Decaux G, Soupart A, Vassart G, &ldquo;Non-Peptide Arginine-Vasopressin Antagonists: The Vaptans,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9624):1624-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11654/abstract-text/18468546/pubmed\" id=\"18468546\" target=\"_blank\">",
"        18468546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gheorghiade M, Konstam MA, Burnett JC Jr, &ldquo;Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 297(12):1332-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11654/abstract-text/17384438/pubmed\" id=\"17384438\" target=\"_blank\">",
"        17384438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konstam MA, Gheorghiade M, Burnett JC Jr, et al, &ldquo;Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 297(12):1319-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11654/abstract-text/17384437/pubmed\" id=\"17384437\" target=\"_blank\">",
"        17384437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McNeely EB, Hull JH, Adams KF, et al, &ldquo;Comparison of the Relative Oral Bioavailability of Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact,&rdquo; 2012, 25 (abstract 25 ACCP)",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oghlakian G and Klapholz M, &ldquo;Vasopressin and Vasopressin Receptor Antagonists in Heart Failure,&rdquo;",
"      <i>",
"       Cardiol Rev",
"      </i>",
"      , 2009, 17(1):10-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11654/abstract-text/19092365/pubmed\" id=\"19092365\" target=\"_blank\">",
"        19092365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shoaf SE, Bramer SL, Bricmont P, et al, &ldquo;Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan, a Non-peptide AVP Antagonist, and Furosemide or Hydrochlorothiazide,&rdquo;",
"      <i>",
"       J Cardiovasc Pharmacol",
"      </i>",
"      , 2007, 50(2):213-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11654/abstract-text/17703139/pubmed\" id=\"17703139\" target=\"_blank\">",
"        17703139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shoaf SE, Elizari MV, Wang Z, et al, &ldquo;Tolvaptan Administration Does Not Affect Steady State Amiodarone Concentrations in Patients With Cardiac Arrhythmias,&rdquo;",
"      <i>",
"       J Cardiovasc Pharmacol Ther",
"      </i>",
"      , 2005, 10(3):165-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11654/abstract-text/16211205/pubmed\" id=\"16211205\" target=\"_blank\">",
"        16211205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9512 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11654=[""].join("\n");
var outline_f11_24_11654=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055924\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810723\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7794510\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276923\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810547\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810606\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810607\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13797229\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13797228\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810612\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276924\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810545\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11213964\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810608\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810548\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810564\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810553\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810554\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838565\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7832267\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810568\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810549\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810550\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810552\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810581\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321967\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810610\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390224\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810582\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7810571\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9512\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9512|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/62/19429?source=related_link\">",
"      Tolvaptan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_24_11655="Treatment of oligodendroglial tumors";
var content_f11_24_11655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Treatment of oligodendroglial tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/24/11655/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11655/contributors\">",
"     Martin van den Bent, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/24/11655/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11655/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11655/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/24/11655/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11655/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/24/11655/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oligodendroglial tumors constitute between 5 and 20 percent of all glial tumors. Oligodendroglial tumors typically arise in the fourth to sixth decades, with low-grade oligodendrogliomas and oligoastrocytomas occurring at an earlier age than anaplastic oligodendrogliomas and anaplastic oligoastrocytomas. Despite the prolonged clinical course seen with oligodendroglial tumors, the outcome is almost always fatal.",
"   </p>",
"   <p>",
"    The treatment of oligodendroglial tumors will be reviewed here. The clinical manifestations, pathology, and molecular prognostic factors of oligodendroglial tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44103?source=see_link\">",
"     \"Clinical features, pathology, and prognostic factors for oligodendroglial tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANAPLASTIC OLIGODENDROGLIAL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the management of patients with anaplastic oligodendroglial tumors was based upon results from studies in patients with malignant gliomas, carried out prior to the recognition of the differences between oligodendroglial and other glial tumors. Surgery remains the initial treatment modality for most patients. Radiation therapy (RT) and chemotherapy are important components of the management for these patients as well as for those with large low-grade oligodendroglial tumors that are not completely resected.",
"   </p>",
"   <p>",
"    Contemporary clinical trials are focusing on the role of molecular markers as prognostic and predictive markers in patients with anaplastic oligodendroglial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In general, the presence of",
"    <span class=\"nowrap\">",
"     1p/19q",
"    </span>",
"    codeletion, MGMT promoter methylation, or IDH1 mutations is associated with a significantly improved prognosis and longer overall survival. Codeletion of",
"    <span class=\"nowrap\">",
"     1p/19q",
"    </span>",
"    is also predictive of an improved response to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44103?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features, pathology, and prognostic factors for oligodendroglial tumors\", section on 'Codeletion 1p/19q'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery provides tissue to establish the diagnosis and is used to relieve symptoms due to mass effect in patients with oligodendroglial tumors. In addition, gross total resection of the tumor is recommended if possible as part of the initial treatment in an effort to improve the long-term prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44568?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of low-grade glioma\", section on 'Surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\", section on 'Extent of resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials that have established the benefit of maximal surgical resection compared with a more limited resection, and such studies are unlikely to be conducted. Evidence supporting this approach specifically in oligodendroglial tumors comes from secondary analyses of two large trials, which demonstrated a positive association between a more extensive resection and prolonged survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, in retrospective studies, small, superficial tumors with a relatively favorable prognosis are more likely to have been extensively resected, while large, deep-seated, or midline tumors with a poorer prognosis will not have been completely resected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following surgery, further treatment (RT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy) is recommended for patients with anaplastic tumors, as well as for selected patients with low-grade tumors with focal deficits or residual lesions with mass effect. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Low-grade oligodendroglial tumors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175763196\">",
"    <span class=\"h2\">",
"     Postoperative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both RT and chemotherapy are active treatment modalities for patients with oligodendroglial tumors. Historically, various treatment strategies have been evaluated following surgery including RT with deferred chemotherapy, chemotherapy with deferred RT, RT followed immediately by adjuvant chemotherapy, and neoadjuvant chemotherapy followed by RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175764189\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials that included high-grade gliomas of all types demonstrated that adjuvant RT with doses of 60 to 65 Gy in 30 to 35 fractions provides a significant survival benefit. The effectiveness of RT has not been assessed in randomized trials specifically looking at patients with oligodendroglial tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=see_link\">",
"     \"Adjuvant radiation therapy for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although retrospective studies have given conflicting results about whether postoperative RT prolongs survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/4-9\">",
"     4-9",
"    </a>",
"    ], RT has been considered an integral component of the treatment for patients with anaplastic lesions or a large residual tumor. The recognition that oligodendroglial tumors are sensitive to chemotherapy has led to trials that are reexamining the sequence in which RT and chemotherapy are administered. (See",
"    <a class=\"local\" href=\"#H175763196\">",
"     'Postoperative therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Recurrent disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175764248\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oligodendroglial tumors are markedly more sensitive to chemotherapy than nonoligodendroglial tumors.",
"   </p>",
"   <p>",
"    This chemosensitivity was initially demonstrated with a PCV regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ) in patients who had recurred or progressed after RT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. These observations led to the evaluation of PCV as part of a combined modality approach for the initial management of these patients, as well as to its use in the treatment of recurrent disease. Subsequent studies showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    is also highly active [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials in patients treated with chemotherapy only that directly compare PCV and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . Temozolomide is generally preferred over the PCV regimen, based upon its ease of administration and better patient tolerance, although PCV remains an option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175764745\">",
"    <span class=\"h3\">",
"     RT plus chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two cooperative group randomized phase III trials with prolonged follow-up provide strong, complementary evidence that a combination of both RT and chemotherapy following surgery is associated with an improvement in survival on long-term follow-up in the subset of patients with codeletion of",
"    <span class=\"nowrap\">",
"     1p/19q.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175763382\">",
"    <span class=\"h4\">",
"     EORTC 26951",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the EORTC 26951 trial, 368 patients were randomly assigned to immediate RT only or RT followed by six cycles of PCV [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/2\">",
"     2",
"    </a>",
"    ]. The total dose of RT on each treatment arm was 60 Gy. The results of this trial were originally published in 2006 with a median follow-up of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/18\">",
"     18",
"    </a>",
"    ]. The results of the trial were updated in 2012 with a median follow-up of almost 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients were eligible to receive additional treatment after progression following their initial management. Among patients who initially were treated with RT plus PCV, 53 percent received subsequent chemotherapy, primarily with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . Among those who were given RT alone, 88 percent received subsequent chemotherapy, generally with PCV",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temozolomide.",
"   </p>",
"   <p>",
"    Results from EORTC 26951 include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a median follow-up of 60 months [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/18\">",
"       18",
"      </a>",
"      ], progression-free survival (PFS) was already significantly prolonged with adjuvant PCV compared to RT alone (23 versus 13 months), but the difference in overall survival at that time was not statistically significant (40 versus 31 months without adjuvant chemotherapy).",
"     </li>",
"     <li>",
"      With more prolonged follow-up, the survival curves with the two initial treatment regimens diverged [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/20\">",
"       20",
"      </a>",
"      ], and the benefit from initial combined chemotherapy (PCV) and RT was seen primarily in patients whose tumors contained the",
"      <span class=\"nowrap\">",
"       1p/19q",
"      </span>",
"      codeletion. Samples from 316 of 368 patients (86 percent) were available for analysis for",
"      <span class=\"nowrap\">",
"       1p/19q",
"      </span>",
"      codeletion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among the 80 patients whose tumor contained the",
"      <span class=\"nowrap\">",
"       1p/19q",
"      </span>",
"      codeletion, PFS was significantly increased when patients were treated with RT plus PCV compared with RT alone (median 157 versus 50 months, HR 0.42, 95% CI 0.24-0.74), and there was a trend toward increase in overall survival (median not reached versus 112 months, HR 0.56, 95% CI 0.31-1.03).",
"     </li>",
"     <li>",
"      In the 236 patients whose tumor did not have the",
"      <span class=\"nowrap\">",
"       1p/19q",
"      </span>",
"      codeletion, the prognosis was substantially worse and the impact of adding chemotherapy to RT was limited (PFS median 15 versus 9 months, HR 0.73, 95% CI 0.56-0.97, and overall survival median 25 versus 21 months, HR 0.83, 95% CI 0.62-1.10).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175763225\">",
"    <span class=\"h4\">",
"     RTOG 9402",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the RTOG 9402 trial, 291 patients with anaplastic oligodendrogliomas or anaplastic oligoastrocytomas were eligible for analysis after random assignment to either four cycles of intensified PCV followed by RT or immediate RT without chemotherapy. The cumulative dose of RT on both treatment arms was 60 Gy. The results of RTOG 9402 were originally published in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/1\">",
"     1",
"    </a>",
"    ] and were subsequently updated in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the initial report of results from this trial [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/1\">",
"       1",
"      </a>",
"      ], PFS was significantly increased with PCV followed by RT compared with RT alone (2.6 versus 1.7 years), but the difference in overall survival was not significant (4.9 versus 4.7 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With 11.3 years follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/21\">",
"       21",
"      </a>",
"      ], however, results were dependent upon the molecular characteristics of the tumor and were consistent with those seen in the EORTC 26951 trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients whose tumors contained the",
"      <span class=\"nowrap\">",
"       1p/19q",
"      </span>",
"      codeletion, overall survival was significantly prolonged in patients treated with intensified PCV followed by RT compared with those given only RT initially (median 14.7 versus 7.3 years, HR 0.59, 95% CI 0.37-0.95).",
"     </li>",
"     <li>",
"      For patients whose tumors did not contain the",
"      <span class=\"nowrap\">",
"       1p/19q",
"      </span>",
"      codeletion, prognosis was again substantially worse, and the impact of therapy not statistically significant (median survival 2.6 versus 2.7 years, HR 0.85, 95% CI 0.58-1.23).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Chemotherapy and deferred RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensitivity of oligodendroglial tumors to chemotherapy led to the evaluation of chemotherapy rather than RT as the initial treatment after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The goal of this approach is to minimize late neurotoxicity caused by RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This approach was evaluated in a phase III trial (NOA-4) that included patients with anaplastic astrocytomas, anaplastic oligoastrocytomas, and oligodendrogliomas. There was no significant difference in time to treatment failure either in patients with oligodendroglial tumors or those with malignant astrocytomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link&amp;anchor=H13#H13\">",
"     \"Adjuvant chemotherapy for malignant gliomas\", section on 'Adjuvant chemotherapy with delayed RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175763882\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results from the EORTC 26951 and RTOG 9402 trials have established that a combination of chemotherapy and RT following surgery results in a clinically meaningful prolongation in overall survival compared with RT alone for patients with a grade III oligodendroglial tumor and codeletion of",
"    <span class=\"nowrap\">",
"     1p/19q.",
"    </span>",
"   </p>",
"   <p>",
"    The optimal chemotherapy regimen (PCV or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    ) remains uncertain, as does the relative timing of RT and chemotherapy. A PCV (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ) regimen has been validated in these phase III trials, but temozolomide is easier to administer and is better tolerated.",
"   </p>",
"   <p>",
"    For patients with an oligodendroglial tumor but without a codeletion of",
"    <span class=\"nowrap\">",
"     1p/19q,",
"    </span>",
"    the prognosis is significantly worse, and the benefits of adding chemotherapy to postoperative adjuvant RT remain uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both PCV and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    have activity in patients who have failed an initial chemotherapy regimen, although response rates are lower and the duration of disease control is generally shorter compared to treatment at first diagnosis or at first recurrence after RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551957497\">",
"    <span class=\"h3\">",
"     Temozolomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most trials of second-line chemotherapy have evaluated the activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    in patients who received prior PCV, either given as an adjuvant or at first recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    after failure with PCV was illustrated by a retrospective series of 48 patients with anaplastic oligodendrogliomas and oligoastrocytomas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/26\">",
"     26",
"    </a>",
"    ]. In this series, 21 patients (44 percent) had an objective response, including eight with a complete remission. The median PFS was 7 months and the median overall survival was 10 months. Treatment was well tolerated, and the primary toxicity was thrombocytopenia. In other series on similar patients, an objective response rate of 25 percent was noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551957518\">",
"    <span class=\"h3\">",
"     PCV regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with PCV after progression on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    is more limited. Nonetheless, there is evidence that PCV is active in some patients who have progressed after previous treatment with temozolomide. In a retrospective study of 24 patients, second-line PCV induced an objective response in 17 percent of cases, 50 percent were progression-free at six months, and 21 percent were progression-free at 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551957504\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    has some activity in patients with recurrent glioblastoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36328?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of recurrent malignant gliomas\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Solid data are lacking, all results are from uncontrolled studies and are consistent with short duration effects consistent with a normalization of vasculature and anti-edema effect, despite high response rates. A retrospective analysis of 22 patients with recurrent, alkylator-refractory anaplastic oligodendroglioma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/28\">",
"     28",
"    </a>",
"    ] (all with codeletion of",
"    <span class=\"nowrap\">",
"     1p/19q",
"    </span>",
"    and previously treated with surgery, RT, adjuvant chemotherapy, and one chemotherapy regimen for recurrent disease) noted a partial response observed in 15 cases (68 percent). Despite that, the median time to progression and median survival in this cohort were only 6.8 and 8.5 months, respectively. Another series of 25 patients with recurrent oligodendroglial tumors recurrent after RT and at least one chemotherapy regimen observed an objective response rate of 72 percent with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , with a median progression-free survival of only 140 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/29\">",
"     29",
"    </a>",
"    ]. No clear correlation was found between the genotype and outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551957511\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients who have progressed on either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    or PCV is experimental. Other agents that have shown some activity as second-line chemotherapy in patients with anaplastic oligodendroglial tumors include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , and the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . Response rates with these agents have generally been low (less than 15 percent), and almost all patients' progress in less than 12 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link\">",
"     \"Experimental treatment approaches for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LOW-GRADE OLIGODENDROGLIAL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with low-grade oligodendroglial tumors is dependent upon the size of the tumor and the extent of symptomatology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78208085\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of patients with small, minimally symptomatic low-grade glial tumors remains controversial. Many of these patients will remain stable for a protracted period without treatment, and some physicians recommend deferring treatment until there is clinical or imaging evidence of progression. This may result in a deferred tissue diagnosis, and many of these patients will ultimately be found to have oligodendroglial tumors. The advantages and disadvantages of deferring treatment for patients with presumed low-grade glioma are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44568?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of low-grade glioma\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery is generally indicated for symptomatic patients, for lesions with clear mass effect or showing clear growth. Patients whose only symptoms consist of seizures that can be medically controlled may not require surgery. Most observational studies suggest outcome may be better in patients undergoing early extensive surgery, but it is unclear to what extent that may be due to patient selection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78208092\">",
"    <span class=\"h2\">",
"     Postoperative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with do undergo immediate surgical resection, the decision whether or not to include additional treatment (RT or chemotherapy) depends upon the presence of focal deficits, a residual lesion with mass effect, and whether or not foci containing anaplastic tumor are identified. (See",
"    <a class=\"local\" href=\"#H175764189\">",
"     'Radiation therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H175764248\">",
"     'Chemotherapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44568?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of low-grade glioma\", section on 'Timing of RT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44568?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of low-grade glioma\", section on 'Adjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A \"wait and see\" approach following initial surgery may be followed in young patients with a favorable prognosis whose symptoms are limited to seizures and who have undergone an extensive resection for a low-grade tumor, especially if molecular studies show the presence of a",
"    <span class=\"nowrap\">",
"     1p/19q",
"    </span>",
"    codeletion. These tumors have a lower annual growth rate compared to low grade tumors without",
"    <span class=\"nowrap\">",
"     1p/19q",
"    </span>",
"    codeletion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44103?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features, pathology, and prognostic factors for oligodendroglial tumors\", section on 'Codeletion of 1p/19q'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy in patients with low-grade oligodendroglial tumors may be associated with a prolonged response, which may develop in a delayed fashion, sometimes even after the end of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/14,31,32\">",
"     14,31,32",
"    </a>",
"    ]. In a series of 21 patients with low-grade gliomas, including 15 oligodendrogliomas and 4 with oligoastrocytomas, patients were treated with PCV chemotherapy for a maximum of six cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/32\">",
"     32",
"    </a>",
"    ]. All patients had progressive disease that was measurable on MRI. Patients were then followed without additional therapy until there was evidence of progression. Overall, 20 of 21 patients had an ongoing decrease in mean tumor diameter after completion of chemotherapy, with a median duration of over three years.",
"   </p>",
"   <p>",
"    These data suggest that an extended course of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    as has been suggested may not be necessary for prolonged disease control. However, in contrast to patients with oligodendroglioma and",
"    <span class=\"nowrap\">",
"     1p/19q",
"    </span>",
"    loss, the duration of benefit from chemotherapy with temozolomide is thought to be more limited in patients with low-grade astrocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H701993522\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no formal clinical trials that define the optimal frequency for follow-up after treatment.",
"   </p>",
"   <p>",
"    Guidelines from the National Comprehensive Cancer Network (NCCN) recommend the following schedule for follow-up imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with malignant gliomas including both anaplastic oligodendrogliomas and anaplastic oligoastrocytomas, a repeat MRI should be obtained two to six weeks after completion of radiation therapy, then every two to four months for two to three years, and less frequently thereafter.",
"     </li>",
"     <li>",
"      For patients with low-grade oligodendroglial tumors, a repeat MRI should be obtained every three to six months for five years, and then at least annually thereafter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1501891\">",
"    <span class=\"h2\">",
"     Assessment of response and progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient management decisions require an assessment of both initial response to treatment as well as subsequent evidence of progressive disease. Traditionally, this approach has used the Macdonald criteria which rely upon measurement of areas of contrast enhancement [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New criteria have been proposed by the Response Assessment in Neuro-Oncology (RANO) working group to address problems in assessing patients with pseudoprogression or in assessing progressive disease in patients with nonenhancing lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11655/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4821?source=see_link\">",
"     \"Assessment of disease status and surveillance after treatment in patients with brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oligodendrogliomas (ODs) and oligoastrocytomas (OAs) have important differences from other glial tumors, with significant ramifications for patient management. Many of these tumors contain a characteristic codeletion of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q), which has been correlated with both a striking sensitivity to chemotherapy and a more prolonged natural history, independent of specific treatment. Tissue should be tested whenever possible to determine whether codeletion of chromosomes 1p and 19q is present. Testing for IDH mutations should be considered, although this will not alter patient management. (See",
"    <a class=\"local\" href=\"#H175764248\">",
"     'Chemotherapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44103?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features, pathology, and prognostic factors for oligodendroglial tumors\", section on 'Codeletion of 1p/19q'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anaplastic oligodendrogliomas and oligoastrocytomas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a newly-diagnosed anaplastic oligodendroglioma or oligoastrocytoma, we recommend maximal surgical resection consistent with preservation of neurologic function (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Although gross total resection is preferred whenever possible, subtotal resection or stereotactic biopsy may be required depending upon the location and extent of the tumor. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients whose tumor contains the characteristic",
"      <span class=\"nowrap\">",
"       1p/19q",
"      </span>",
"      codeletion, we recommend adjuvant treatment that includes both radiation therapy (RT) and chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Whether chemotherapy should be given before or after RT remains uncertain. Although PCV (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"       lomustine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ) has been demonstrated to be effective in two phase III trials,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      is easier to administer and has better patient tolerance. (See",
"      <a class=\"local\" href=\"#H175763196\">",
"       'Postoperative therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients whose tumor does not contain the",
"      <span class=\"nowrap\">",
"       1p/19q",
"      </span>",
"      codeletion, we suggest postoperative RT, with chemotherapy withheld until there is evidence of disease progression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H175763196\">",
"       'Postoperative therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Low-grade oligodendrogliomas and oligoastrocytomas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For young patients with transient symptoms and a small tumor not creating a mass effect on adjacent structures, we suggest maximal surgical resection if safely possible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For young favorable prognosis patients (eg, under 50 years of age presenting without focal deficits or signs of increased intracranial pressure) who have undergone surgical resection, we suggest that further treatment with either RT or chemotherapy be deferred until there is evidence of recurrence or progression of symptoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Low-grade oligodendroglial tumors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44568?source=see_link\">",
"       \"Management of low-grade glioma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Careful observation is an alternative to immediate surgery in these patients, with surgery reserved until there is clinical or imaging evidence of progressive disease. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Low-grade oligodendroglial tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients presenting with poor prognostic features (a large mass, extensive neurologic symptoms, an age above 40 to 50 years), we recommend immediate surgery to debulk the tumor and establish the diagnosis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44103?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical features, pathology, and prognostic factors for oligodendroglial tumors\", section on 'Codeletion of 1p/19q'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Single modality treatment with either chemotherapy or RT alone is indicated in those patients whose tumors contain the chromosome",
"      <span class=\"nowrap\">",
"       1p/19q",
"      </span>",
"      deletions. Chemotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      or PCV) can be considered for the initial postoperative treatment of residual or progressive disease in lieu of RT because of the prolonged natural history of the disease in these patients. RT is then reserved for progression after chemotherapy. Whether combining RT with adjuvant PCV will also prolong survival here is still unknown. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Chemotherapy and deferred RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients whose tumors do not contain the",
"      <span class=\"nowrap\">",
"       1p/19q",
"      </span>",
"      codeletion, we suggest that RT be administered postoperatively (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Chemotherapy should be reserved for patients with progressive symptoms following RT. (See",
"      <a class=\"local\" href=\"#H175764189\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1501967\">",
"    <span class=\"h2\">",
"     Posttreatment surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with oligodendroglial tumors should be followed after treatment with imaging. For those with anaplastic lesions, a repeat MRI should be obtained two to six weeks after completion of radiation therapy, then every two to four months for two to three years, and less frequently thereafter. For those with low-grade tumors, repeat MRI should be obtained every three to six months for five years, and then at least annually thereafter. (See",
"    <a class=\"local\" href=\"#H701993522\">",
"     'Surveillance after treatment'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/1\">",
"      Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24:2707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/2\">",
"      van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/3\">",
"      Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002; 20:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/4\">",
"      Shaw EG, Scheithauer BW, O'Fallon JR, et al. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992; 76:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/5\">",
"      Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS. The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 1994; 30:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/6\">",
"      Wallner KE, Gonzales M, Sheline GE. Treatment of oligodendrogliomas with or without postoperative irradiation. J Neurosurg 1988; 68:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/7\">",
"      Celli P, Nofrone I, Palma L, et al. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994; 35:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/8\">",
"      Bullard DE, Rawlings CE 3rd, Phillips B, et al. Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 1987; 60:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/9\">",
"      Nijjar TS, Simpson WJ, Gadalla T, McCartney M. Oligodendroglioma. The Princess Margaret Hospital experience (1958-1984). Cancer 1993; 71:4002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/10\">",
"      Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer 2004; 101:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/11\">",
"      Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/12\">",
"      van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998; 51:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/13\">",
"      Soffietti R, Rud&agrave; R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998; 43:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/14\">",
"      Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996; 46:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/15\">",
"      Buckner JC, Gesme D Jr, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003; 21:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/16\">",
"      Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006; 24:4746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/17\">",
"      van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003; 21:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/18\">",
"      Kouwenhoven MC, Gorlia T, Kros JM, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol 2009; 11:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/19\">",
"      van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/20\">",
"      van den Bent M, Hoang-Xuan K, Ariela Brandes A, et al. Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD) (abstract #2). J Clin Oncol 2012; 30s:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/21\">",
"      Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/22\">",
"      Cairncross JG, Wang M, Shaw EG, et al. Chemotherapy plus radiotherapy versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study (abstract #2008b). J Clin Oncol 2012; 30s:2008b.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/23\">",
"      Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T. Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 2006; 79:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/24\">",
"      Abrey LE, Childs BH, Paleologos N, et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol 2006; 8:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/25\">",
"      van den Bent MJ, Keime-Guibert F, Brandes AA, et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 2001; 57:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/26\">",
"      Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001; 19:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/27\">",
"      Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 2004; 63:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/28\">",
"      Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 2009; 115:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/29\">",
"      Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 2009; 72:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/30\">",
"      Ricard D, Kaloshi G, Amiel-Benouaich A, et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 2007; 61:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/31\">",
"      Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005; 103:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/32\">",
"      Peyre M, Cartalat-Carel S, Meyronet D, et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol 2010; 12:1078.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN guidelines file://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/34\">",
"      Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/35\">",
"      Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11655/abstract/36\">",
"      van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011; 12:583.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5221 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-163.177.76.26-8B01C67036-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11655=[""].join("\n");
var outline_f11_24_11655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANAPLASTIC OLIGODENDROGLIAL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175763196\">",
"      Postoperative therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175764189\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175764248\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175764745\">",
"      - RT plus chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H175763382\">",
"      EORTC 26951",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H175763225\">",
"      RTOG 9402",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chemotherapy and deferred RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H175763882\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H551957497\">",
"      - Temozolomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H551957518\">",
"      - PCV regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H551957504\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H551957511\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LOW-GRADE OLIGODENDROGLIAL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78208085\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78208092\">",
"      Postoperative therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H701993522\">",
"      SURVEILLANCE AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1501891\">",
"      Assessment of response and progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anaplastic oligodendrogliomas and oligoastrocytomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Low-grade oligodendrogliomas and oligoastrocytomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1501967\">",
"      Posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=related_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=related_link\">",
"      Adjuvant radiation therapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4821?source=related_link\">",
"      Assessment of disease status and surveillance after treatment in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44103?source=related_link\">",
"      Clinical features, pathology, and prognostic factors for oligodendroglial tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44568?source=related_link\">",
"      Management of low-grade glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36328?source=related_link\">",
"      Management of recurrent malignant gliomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_24_11656="Nitroglycerin (glyceryl trinitrate): Drug information";
var content_f11_24_11656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitroglycerin (glyceryl trinitrate): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/10/9382?source=see_link\">",
"    see \"Nitroglycerin (glyceryl trinitrate): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/7/34934?source=see_link\">",
"    see \"Nitroglycerin (glyceryl trinitrate): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Minitran&trade;;",
"     </li>",
"     <li>",
"      Nitro-Bid&reg;;",
"     </li>",
"     <li>",
"      Nitro-Dur&reg;;",
"     </li>",
"     <li>",
"      Nitro-Time&reg;;",
"     </li>",
"     <li>",
"      Nitrolingual&reg;;",
"     </li>",
"     <li>",
"      NitroMist&reg;;",
"     </li>",
"     <li>",
"      Nitrostat&reg;;",
"     </li>",
"     <li>",
"      Rectiv&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Minitran&trade;;",
"     </li>",
"     <li>",
"      Mylan-Nitro Sublingual Spray;",
"     </li>",
"     <li>",
"      Nitro-Dur&reg;;",
"     </li>",
"     <li>",
"      Nitroglycerin Injection, USP;",
"     </li>",
"     <li>",
"      Nitrol&reg;;",
"     </li>",
"     <li>",
"      Nitrostat&reg;;",
"     </li>",
"     <li>",
"      Rho&reg;-Nitro Pump Spray;",
"     </li>",
"     <li>",
"      Transderm-Nitro&reg;;",
"     </li>",
"     <li>",
"      Trinipatch&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F202148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F202103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Hemodynamic and antianginal tolerance often develop within 24-48 hours of continuous nitrate administration. Nitrate-free interval (10-12 hours/day) is recommended to avoid tolerance development; gradually decrease dose in patients receiving NTG for prolonged period to avoid withdrawal reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Angina/coronary artery disease:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     2.5-6.5 mg 3-4 times/day (maximum dose: 26 mg 4 times/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     5 mcg/minute, increase by 5 mcg/minute every 3-5 minutes to 20 mcg/minute. If no response at 20 mcg/minute, may increase by 10-20 mcg/minute every 3-5 minutes (generally accepted maximum dose: 400 mcg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Topical ointment:",
"     </i>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; upon rising and",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; 6 hours later; if necessary, the dose may be doubled to 1&rdquo; and subsequently doubled again to 2&rdquo; if  response is inadequate. Doses of",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; to 2&rdquo; were used in clinical trials. Recommended maximum: 2 doses/day; include a nitrate free-interval ~10-12 hours/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Topical patch, transdermal:",
"     </i>",
"     0.2-0.4 mg/hour initially and titrate to doses of 0.4-0.8 mg/hour. Tolerance is minimized by using a patch-on period of 12-14 hours/day and patch-off period of 10-12 hours/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sublingual:",
"     </i>",
"     0.3-0.6 mg every 5 minutes for maximum of 3 doses in 15 minutes; may also use prophylactically 5-10 minutes prior to activities which may provoke an attack.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Translingual:",
"     </i>",
"     1-2 sprays onto or under tongue every 3-5 minutes for maximum of 3 doses in 15 minutes, may also be used prophylactically 5-10 minutes prior to activities which may provoke an angina attack",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anal fissure, chronic (0.4% ointment):",
"     </b>",
"     Intra-anal: 1 inch (equals 1.5 mg of nitroglycerin) every 12 hours for up to 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Esophageal spastic disorders (unlabeled use):",
"     </b>",
"     Sublingual: 0.3-0.6 mg (Swamy, 1977)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uterine relaxation (unlabeled use):",
"     </b>",
"     I.V. bolus: 100-200 mcg; may repeat dose every 2 minutes as necessary (Axemo, 1998; Chandraharan, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F202104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, translingual: 400 mcg/spray (4.1 g, 8.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NitroMist&reg;: 400 mcg/spray (8.5 g) [230 metered sprays]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 2.5 mg, 6.5 mg, 9 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitro-Time&reg;: 2.5 mg, 6.5 mg, 9 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 25 mg (250 mL) [100 mcg/mL]; 50 mg (500 mL) [100 mcg/mL]; 50 mg (250 mL) [200 mcg/mL]; 100 mg (250 mL) [400 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 5 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectiv&reg;: 0.4% (30 g) [contains propylene glycol; ~1.5 mg/inch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitro-Bid&reg;: 2% (1 g, 30 g, 60 g) [~15 mg/inch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal: 0.1 mg/hr (30s); 0.2 mg/hr (30s); 0.4 mg/hr (30s); 0.6 mg/hr (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minitran&trade;: 0.1 mg/hr (30s); 0.2 mg/hr (30s); 0.4 mg/hr (30s); 0.6 mg/hr (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitro-Dur&reg;: 0.1 mg/hr (30s); 0.2 mg/hr (30s); 0.3 mg/hr (30s); 0.4 mg/hr (30s); 0.6 mg/hr (30s); 0.8 mg/hr (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, translingual [spray]: 0.4 mg/spray (4.9 g, 12 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitrolingual&reg;: 0.4 mg/spray (12 g) [contains ethanol 20%; 200 metered sprays]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitrolingual&reg;: 0.4 mg/spray (4.9 g) [contains ethanol 20%; 60 metered sprays]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitrostat&reg;: 0.3 mg, 0.4 mg, 0.6 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule, infusion, injection, patch, solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V.: Prepare in glass bottles, EXCEL&reg; or PAB&reg; containers. Adsorption occurs to soft plastic (eg, PVC); use administration sets intended for nitroglycerin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Intra-anal ointment: Using a finger covering (eg, plastic wrap, surgical glove, finger cot), place finger beside 1 inch measuring guide on the box and squeeze ointment the length of the measuring line directly onto covered finger. Insert ointment into the anal canal using the covered finger up to first finger joint (do not insert further than the first finger joint) and apply ointment around the side of the anal canal. If intra-anal application is too painful, may apply the ointment to the outside of the anus. Wash hands following application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Oral (extended release capsule): Swallow whole. Do not chew, break, or crush. Take with a full glass of water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Sublingual: Do not crush sublingual product (tablet). Place under tongue and allow to dissolve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Topical ointment: Wash hands prior to and after use. Application site should be clean, dry, and hair-free. Apply to chest or back with the applicator or dose-measuring paper. Spread in a thin layer over a 2.25 x 3.5 inch area. Do not rub into skin. Tape applicator into place.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Topical patch, transdermal: Application site should be clean, dry and hair-free. Remove patch after 12-14 hours. Rotate patch sites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Translingual spray: Do not shake container. Prior to initial use, the pump must be primed by spraying 5 times (Nitrolingual&reg;) or 10 times (Nitromist&reg;) into the air. Priming sprays should be directed away from patient and others. Release spray onto or under tongue. Close mouth after administration. Do not rinse the mouth for at least 5-10 minutes. The end of the pump should be covered by the fluid in the bottle. If pump is unused for 6 weeks, a single priming spray (Nitrolingual&reg;) or 2 priming sprays (Nitromist&reg;) should be completed.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     50 mg in 250 mL (concentration: 200",
"     <b>",
"      mcg",
"     </b>",
"     /mL)",
"     <b>",
"      or",
"     </b>",
"     100 mg in 250 mL (concentration: 400",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     100",
"     <b>",
"      mcg",
"     </b>",
"     /mL, 200",
"     <b>",
"      mcg",
"     </b>",
"     /mL, or 400",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F202155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, amphotericin B cholesteryl sulfate complex, argatroban, atracurium, bivalirudin, cisatracurium, clonidine, dexmedetomidine, diltiazem, dobutamine, dobutamine with dopamine, dobutamine with lidocaine, dobutamine with nitroprusside, dopamine, dopamine with lidocaine, dopamine with nitroprusside, drotrecogin alfa, epinephrine, eptifibatide, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, haloperidol, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, inamrinone, insulin (regular), labetalol, lidocaine, lidocaine with nitroprusside, linezolid, lorazepam, micafungin, midazolam, milrinone, morphine, nesiritide, nicardipine, nitroprusside, norepinephrine, pancuronium, propofol, ranitidine, remifentanil, tacrolimus, theophylline, thiopental, tirofiban, vasopressin, vecuronium, warfarin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caffeine citrate, levofloxacin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Alteplase, furosemide, heparin, hydralazine, metoprolol, pantoprazole, tenecteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caffeine citrate, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F202079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment or prevention of angina pectoris",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Intravenous (I.V.) administration: Treatment or prevention of angina pectoris; acute decompensated  heart failure (especially when associated with acute myocardial infarction); perioperative hypertension (especially during cardiovascular surgery); induction of intraoperative hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Intra-anal administration (Rectiv&trade; ointment): Treatment of moderate-to-severe pain associated with chronic anal fissure",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F202144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term management of pulmonary hypertension (I.V.); esophageal spastic disorders; uterine relaxation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F202157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitroglycerin may be confused with nitrofurantoin, nitroprusside",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitro-Bid&reg; may be confused with Macrobid&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitroderm may be confused with NicoDerm&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitrol may be confused with Nizoral&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitrostat&reg; may be confused with Nilstat, nystatin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nitrocor [Italy, Russia, and Venezuela] may be confused with Natrecor brand name for nesiritide [U.S., Canada, and multiple international markets]; Nutracort brand name for hydrocortisone in the [U.S. and multiple international markets]; Nitro-Dur [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F202146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing, hypotension, orthostatic hypotension, peripheral edema, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (common), dizziness, lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting,  xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, anaphylactoid reaction, application site irritation (patch), blurred vision, cardiovascular collapse, contact dermatitis (ointment, patch), crescendo angina, exfoliative dermatitis, fixed drug eruption (ointment, patch), methemoglobinemia (rare; overdose), pallor, palpitation, rash, rebound hypertension, restlessness, shock, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F202082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to organic nitrates or any component of the formulation (includes adhesives for transdermal product); concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil, or vardenafil); increased intracranial pressure; severe anemia",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Additional contraindications for I.V. product: Constrictive pericarditis; pericardial tamponade; restrictive cardiomyopathy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     According to the 2010 American Heart Association guidelines for the treatment of acute coronary syndromes, nitrates are considered contraindicated in the following conditions: Hypotension (SBP &lt;90 mm Hg or &ge;30 mm Hg below baseline), extreme bradycardia (&lt;50 bpm), tachycardia in the absence of heart failure (&gt;100 bpm), and right ventricular infarction (O&rsquo;Connor, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F202065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/bradycardia: Severe hypotension can occur; paradoxical bradycardia and increased angina pectoris can accompany hypotension. Orthostatic hypotension can also occur; ethanol can accentuate this. Use with caution in volume depletion, moderate hypotension, and extreme caution with inferior wall MI and suspected right ventricular involvement. Use considered contraindicated in patients with severe hypotension (SBP &lt;90 mm Hg or &ge;30 mm Hg below baseline), extreme bradycardia (&lt;50 bpm), and right ventricular MI (O&rsquo;Connor, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intracranial pressure: Nitroglycerin may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM): Avoid use in patients with HCM with outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (Gersh, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PDE-5 inhibitors: Avoid concurrent use with PDE-5 inhibitors (eg, sildenafil, tadalafil, vardenafil). When nitrate administration becomes medically necessary, may administer nitrates only if 24 hours have elapsed after use of sildenafil or vardenafil (48 hours after tadalafil use) (Trujillo, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intra-anal ointment: Use caution when treating rectal anal fissures with nitroglycerin in patients with suspected or known significant cardiovascular disorders (eg, cardiomyopathies, heart failure, acute MI); intra-anal nitroglycerin administration may decrease systolic blood pressure and decrease arterial vascular resistance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-acting agents: Avoid use of long-acting agents in acute MI or acute HF; cannot easily reverse effects if adverse events develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transdermal patches: May contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tolerance: Appropriate dosing is needed to minimize tolerance development.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4039431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Nitroglycerin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alteplase: Nitroglycerin may decrease the serum concentration of Alteplase.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Nitroglycerin may diminish the anticoagulant effect of Heparin. Nitroglycerin may decrease the serum concentration of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosiglitazone: Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of myocardial ischemia was reported for users of this combination in a meta-analysis.  Management: Consider alternatives to this combination when possible.  Rosiglitazone prescribing information states that the combination of rosiglitazone and a nitrate is not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4039432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid ethanol (may increase the hypotensive effects of nitroglycerin). Monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice (may worsen hypertension). Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may cause hypotension).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F202072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11313090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased fetal mortality has been observed in animal studies using isosorbide mononitrate and isosorbide dinitrate at doses much higher than those used in humans. Toxic effects were not observed in animal studies following topical administration of nitroglycerin. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F202108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F202085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Nitroglycerin Translingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mcg/spray (4.1 g): $187.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (NitroMist Translingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mcg/spray (4.1 g): $216.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, controlled release",
"     </b>",
"     (Nitro-Time Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (60): $51.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.5 mg (60): $59.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9 mg (60): $66.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, controlled release",
"     </b>",
"     (Nitroglycerin ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (60): $53.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.5 mg (60): $60.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9 mg (60): $66.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Nitro-Bid Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (30 g): $23.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Rectiv Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4% (30 g): $464.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 24-hour",
"     </b>",
"     (Minitran Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/hour (30): $120.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg/hour (30): $124.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg/hour (30): $136.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg/hour (30): $148.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 24-hour",
"     </b>",
"     (Nitro-Dur Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/hour (30): $121.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg/hour (30): $123.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg/hour (30): $137.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg/hour (30): $137.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg/hour (30): $149.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.8 mg/hour (30): $149.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 24-hour",
"     </b>",
"     (Nitroglycerin Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/hour (30): $55.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg/hour (30): $49.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg/hour (30): $55.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg/hour (30): $61.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nitroglycerin in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/mL 5% (250 mL): $6.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg/mL 5% (250 mL): $7.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nitroglycerin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (10 mL): $6.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nitroglycerin Translingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg/spray (4.9 g): $224.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nitrolingual Translingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg/spray (4.9 g): $287.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sublingual",
"     </b>",
"     (Nitrostat Sublingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg (100): $20.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg (25): $11.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6 mg (100): $20.30",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F202074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F202086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Angiderm Patch (KP);",
"     </li>",
"     <li>",
"      Anginine (AU);",
"     </li>",
"     <li>",
"      Angised (HR, SG);",
"     </li>",
"     <li>",
"      Cardinit (PK);",
"     </li>",
"     <li>",
"      Deponit (CL, DE, HU, LU, MY, PE, PH);",
"     </li>",
"     <li>",
"      Deponit NT (HK, IL);",
"     </li>",
"     <li>",
"      Diafusor (LU);",
"     </li>",
"     <li>",
"      Enetege (UY);",
"     </li>",
"     <li>",
"      Epinitril (FR);",
"     </li>",
"     <li>",
"      Glytrin Spray (HK, NZ, SG);",
"     </li>",
"     <li>",
"      Herzer (JP);",
"     </li>",
"     <li>",
"      Lycinate (AU);",
"     </li>",
"     <li>",
"      Millisrol (JP);",
"     </li>",
"     <li>",
"      Minitran (AU, BE, CR, DO, GR, GT, HN, LU, PA, SV, UY);",
"     </li>",
"     <li>",
"      Myovin (IN);",
"     </li>",
"     <li>",
"      Natispray (LU);",
"     </li>",
"     <li>",
"      Niglinar (PE);",
"     </li>",
"     <li>",
"      Nit-Ret (CZ);",
"     </li>",
"     <li>",
"      Nitracor (PL);",
"     </li>",
"     <li>",
"      Nitradisc (LU, MX, PT);",
"     </li>",
"     <li>",
"      Nitradisc TTS (GR);",
"     </li>",
"     <li>",
"      Nitral (ID);",
"     </li>",
"     <li>",
"      Nitriderm TTS (FR);",
"     </li>",
"     <li>",
"      Nitro (FI, HU);",
"     </li>",
"     <li>",
"      Nitro Mack (LU);",
"     </li>",
"     <li>",
"      Nitro Mack Retard (AE, AT, BH, CY, CZ, EG, GR, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nitro Pohl (HU);",
"     </li>",
"     <li>",
"      Nitro-Bid (MY);",
"     </li>",
"     <li>",
"      Nitro-Dur (CH, ES, HU, IT, NO, PL, PT);",
"     </li>",
"     <li>",
"      Nitro-Dur 10 (IL);",
"     </li>",
"     <li>",
"      Nitro-Mack (PL);",
"     </li>",
"     <li>",
"      Nitro-Pflaster (DE);",
"     </li>",
"     <li>",
"      Nitro-Pflaster-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Nitrobaat (BE, NL);",
"     </li>",
"     <li>",
"      Nitrocard (PL);",
"     </li>",
"     <li>",
"      Nitrocerin (GR);",
"     </li>",
"     <li>",
"      Nitrocine (EE, IE, TW);",
"     </li>",
"     <li>",
"      Nitrocine 5 (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nitrocontin (BF, BJ, CI, ET, GH, GM, GN, IE, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nitrocontin Continus (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nitrocor (IT, PT);",
"     </li>",
"     <li>",
"      Nitroderm (VE);",
"     </li>",
"     <li>",
"      Nitroderm TTS (AE, AR, AT, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CN, CY, DE, EC, EG, ES, ET, GH, GM, GN, GY, HR, HU, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, PL, PT, QA, SA, SC, SD, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nitroderm TTS Ext (CZ);",
"     </li>",
"     <li>",
"      Nitroderm TTS-5 (NI);",
"     </li>",
"     <li>",
"      Nitrodisc (BB, BM, BS, BZ, GY, JM, MY, SR, TT);",
"     </li>",
"     <li>",
"      Nitrodom (AR);",
"     </li>",
"     <li>",
"      Nitrodyl (GR, LU);",
"     </li>",
"     <li>",
"      Nitrodyl TTS (GR);",
"     </li>",
"     <li>",
"      Nitrogesic (UY);",
"     </li>",
"     <li>",
"      Nitroglycerinum (PL);",
"     </li>",
"     <li>",
"      Nitroglycerinum prolongatum (PL);",
"     </li>",
"     <li>",
"      Nitrol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nitrolingual (AT, BE, CH, DE, DK, GB, GR, HK, HU, IE, KP, LU, NL, PH, PT, SE);",
"     </li>",
"     <li>",
"      Nitrolingual Spray (KP, NZ, PH);",
"     </li>",
"     <li>",
"      Nitromack Retard (PY);",
"     </li>",
"     <li>",
"      Nitromex (FI, NO, SE);",
"     </li>",
"     <li>",
"      Nitromint (HU, PL, TH);",
"     </li>",
"     <li>",
"      Nitromint Aerosol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nitromint Retard (AE, BB, BH, BM, BS, BZ, CY, EG, GY, IQ, IR, JM, JO, KW, LB, LY, OM, QA, SA, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Nitronal (FR);",
"     </li>",
"     <li>",
"      Nitronal Aqueous (PH);",
"     </li>",
"     <li>",
"      Nitronal Spray (FR);",
"     </li>",
"     <li>",
"      Nitrong (BE, LU);",
"     </li>",
"     <li>",
"      Nitrong Retard (AT, GR);",
"     </li>",
"     <li>",
"      Nitroplast (ES);",
"     </li>",
"     <li>",
"      Nitrostat (PH, TW);",
"     </li>",
"     <li>",
"      Nitrozell Retard (AT, NL);",
"     </li>",
"     <li>",
"      Nysconitrine (LU);",
"     </li>",
"     <li>",
"      Nyserin (PH);",
"     </li>",
"     <li>",
"      Perlinganit (BG, HU, KP, LU, PL);",
"     </li>",
"     <li>",
"      Ratiopharm (DE);",
"     </li>",
"     <li>",
"      Rectogesic (AU, BE, CH, CZ, DE, DK, FI, FR, GB, IE, IL, IT, NL, NO, NZ, PT, SE);",
"     </li>",
"     <li>",
"      Suscard (GB, IE);",
"     </li>",
"     <li>",
"      Sustac (AE, BB, BH, BM, BS, BZ, CY, EG, GY, HR, HU, IQ, IR, JM, JO, KW, LB, LY, OM, QA, SA, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Sustonit (PL);",
"     </li>",
"     <li>",
"      Transiderm Nitro (AU, FI, IE, NL, NO, SE);",
"     </li>",
"     <li>",
"      Tridil (BR);",
"     </li>",
"     <li>",
"      Trimonit (PL);",
"     </li>",
"     <li>",
"      Trinipatch (LU);",
"     </li>",
"     <li>",
"      Trinter (GB, IE);",
"     </li>",
"     <li>",
"      Venitrin (IT);",
"     </li>",
"     <li>",
"      Willlong (LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F202064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nitroglycerin forms free radical nitric oxide. In smooth muscle, nitric oxide activates guanylate cyclase which increases guanosine 3&rsquo;5&rsquo; monophosphate (cGMP) leading to dephosphorylation of myosin light chains and smooth muscle relaxation. Produces a vasodilator effect on the peripheral veins and arteries with more prominent effects on the veins. Primarily reduces cardiac oxygen demand by decreasing preload (left ventricular end-diastolic pressure); may modestly reduce afterload; dilates coronary arteries and improves collateral flow to ischemic regions. For use in rectal fissures, intra-anal administration results in decreased sphincter tone and intra-anal pressure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F202081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Sublingual tablet: 1-3 minutes; Translingual spray: Similar to sublingual tablet; Extended release: ~60 minutes; Topical: 15-30 minutes; Transdermal: ~30 minutes; I.V.: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Sublingual tablet: 5 minutes; Translingual spray: 4-10 minutes; Extended release: 2.5-4 hours; Topical: ~60 minutes; Transdermal: 120 minutes; I.V.: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Sublingual tablet: At least 25 minutes; Translingual spray: Similar to sublingual tablet; Extended release: 4-8 hours (Gibbons, 2002) ; Topical: 7 hours; Transdermal: 10-12 hours; I.V.: 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass effect; metabolized hepatically to glycerol di- and mononitrate metabolites via liver reductase enzyme; subsequent metabolism to glycerol and organic nitrate; nonhepatic metabolism via red blood cells and vascular walls also occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~1-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Axemo P, Fu X, Lindberg B, et al, \"Intravenous Nitroglycerin for Rapid Uterine Relaxation,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 1998, 77(1):50-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/9492718/pubmed\" id=\"9492718\" target=\"_blank\">",
"        9492718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2002, 40(7):1366-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/12383588/pubmed\" id=\"12383588\" target=\"_blank\">",
"        12383588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chandraharan E and Arulkumaran S, \"Acute Tocolysis,\"",
"      <i>",
"       Curr Opin Obstet Gynecol",
"      </i>",
"      , 2005, 17(2):151-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/15758607/pubmed\" id=\"15758607\" target=\"_blank\">",
"        15758607",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheitlin MD, Hutter AM Jr, Brindis RG, et al, &ldquo;ACC/AHA Expert Consensus Document. Use of Sildenafil (Viagra&reg;) in Patients With Cardiovascular Disease. American College of Cardiology/American Heart Association,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):273-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/9935041/pubmed\" id=\"9935041\" target=\"_blank\">",
"        9935041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corwin S and Reiffel JA, &ldquo;Nitrate Therapy for Angina Pectoris. Current Concepts About Mechanism of Action and Evaluation of Currently Available Preparations,&rdquo; A",
"      <i>",
"       rch Intern Med",
"      </i>",
"      , 1985, 145(3):538-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/3919668/pubmed\" id=\"3919668\" target=\"_blank\">",
"        3919668",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(1):66-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/10669188/pubmed\" id=\"10669188\" target=\"_blank\">",
"        10669188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goyal RK, \"Diseases of the Esophagus,\"",
"      <i>",
"       Harrison&rsquo;s Principles of Internal Medicine",
"      </i>",
"      , 14th ed, Fauci AS, Braunwald E, Isselbacher KJ, et al, eds, New York, NY: McGraw-Hill, 1998, 1592.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy JH, &ldquo;Management of Systemic and Pulmonary Hypertension,&rdquo;",
"      <i>",
"       Tex Heart Inst J",
"      </i>",
"      , 2005, 32(4):467-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/16429888/pubmed\" id=\"16429888\" target=\"_blank\">",
"        16429888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Connor RE, Brady W, Brooks SC, et al, \"Part 10: Acute Coronary Syndromes: 2010 American Heart Association Care Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):787-817.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/20956226/pubmed\" id=\"20956226\" target=\"_blank\">",
"        20956226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swamy N, &ldquo;Esophageal Spasm: Clinical and Monometric Response to Nitroglycerin and Long Acting Nitrites,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1977, 72(1):23-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/401445/pubmed\" id=\"401445\" target=\"_blank\">",
"        401445",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trujillo TC and Dobesh PP, &ldquo;Traditional Management of Chronic Stable Angina,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2007, 27(12):1677-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/24/11656/abstract-text/18041888/pubmed\" id=\"18041888\" target=\"_blank\">",
"        18041888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9706 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11656=[""].join("\n");
var outline_f11_24_11656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202098\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202148\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202103\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202104\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202076\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202061\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803176\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472967\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472968\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202155\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202079\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202144\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202157\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202146\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202082\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202065\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299768\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4039431\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4039432\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202072\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11313090\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202108\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202085\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202074\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202086\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202064\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202081\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9706\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9706|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/10/9382?source=related_link\">",
"      Nitroglycerin (glyceryl trinitrate): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/7/34934?source=related_link\">",
"      Nitroglycerin (glyceryl trinitrate): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_24_11657="Chapter 12B: Renal potassium excretion";
var content_f11_24_11657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 12B: Renal potassium excretion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/24/11657/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11657/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11657/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/24/11657/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11657/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/24/11657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11657/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/24/11657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 15, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although small amounts of K+ are lost each day in stool (5 to 10 meq) and sweat (0 to 10 meq), the kidney plays the major role in the maintenance of K+ balance, appropriately varying K+ secretion with changes in dietary intake (normal range is 40 to 120",
"    <span class=\"nowrap\">",
"     meq/day).",
"    </span>",
"    The primary event in urinary K+ excretion is the secretion of K+ from the tubular cell into the lumen in the distal nephron, particularly in the principal cells in the cortical collecting tubule and in the cells in the adjacent connecting segment and outer medullary collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SEGMENTAL POTASSIUM HANDLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequential handling of filtered K+ by the different nephron segments is depicted in the micropuncture experiments in Figure 1 (",
"    <a class=\"graphic graphic_figure graphicRef75456 \" href=\"UTD.htm?11/33/11805\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The clearance of K+ is compared to that of inulin, which is filtered and then is neither reabsorbed nor secreted. As a result, a fall in the",
"    <span class=\"nowrap\">",
"     CK+/Cin",
"    </span>",
"    ratio indicates that K+ has been removed from the tubular fluid (or reabsorbed), and an elevation in the ratio indicates that K+ has been added to the tubular fluid (or secreted). Almost all of the filtered K+ is reabsorbed in the proximal tubule and the loop of Henle, so that less than 10 percent of the filtered load is delivered to the early distal tubule",
"    <span class=\"nowrap\">",
"     (CK+/Cin",
"    </span>",
"    &lt;0.1). Proximal K+ transport appears to passively follow that of Na+ and water [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/5\">",
"     5",
"    </a>",
"    ], whereas reabsorption in the thick ascending limb of the loop of Henle is mediated by the Na+-K+-2Cl- carrier in the luminal membrane (",
"    <a class=\"graphic graphic_figure graphicRef75301 \" href=\"UTD.htm?30/62/31725\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison to these reabsorptive processes, K+ is secreted by the connecting segment, the principal cells in the cortical and outer medullary collecting tubule (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"     figure 3",
"    </a>",
"    ), and the papillary (or inner medullary) collecting duct (as shown by the rising",
"    <span class=\"nowrap\">",
"     CK+/Cin",
"    </span>",
"    ratio in figure 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/1,3,6\">",
"     1,3,6",
"    </a>",
"    ]. Secretion in these segments can be varied according to physiologic needs and is generally responsible for most of urinary K+ excretion.",
"   </p>",
"   <p>",
"    Distal secretion can be partially counteracted by K+ reabsorption by the intercalated cells in the cortical and outer medullary collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This process may be mediated by an active H+-K+-ATPase pump in the luminal membrane, which results in both H+ secretion and K+ reabsorption (",
"    <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The activity of this pump is increased with K+ depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ] and is reduced with K+ loading [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/13\">",
"     13",
"    </a>",
"    ]. The former adaptation is probably responsible for the observation that net K+ reabsorption, not secretion, appropriately occurs in the distal nephron with K+ depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/4,7,10\">",
"     4,7,10",
"    </a>",
"    ]. Selective inhibition of the H+-K+-ATPase pump in the setting of K+ depletion abolishes distal K+ reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Medullary recycling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The K+ reabsorbed in the thick ascending limb initially enters the medullary interstitium. Some of this K+ is then secreted into either the S3 segment of the late proximal tubule or the thin descending limb of the loop of Henle; this extra K+ can be reabsorbed again when it enters the outer medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, K+ is recycled within the medulla, resulting in the attainment of a relatively high concentration in the interstitium&dagger;. The physiologic function of this phenomenon is uncertain. It is possible, for example, that K+ accumulation in the interstitium promotes K+ excretion by minimizing the degree of passive backleak out of the collecting tubular lumen (where the highest urine K+ concentrations are attained). The high interstitial K+ concentration also may contribute to K+ excretion by a second mechanism, by diminishing the gradient for passive K+ reabsorption via the Na+-K+-2Cl- carrier in the loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &dagger; This process is similar to NH4+ recycling between the loop of Henle and the medullary collecting tubule that promotes net NH4+ excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=see_link&amp;anchor=H10#H10\">",
"     \"Chapter 11A: Renal hydrogen excretion\", section on 'Ammonium excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CELL MODEL FOR POTASSIUM SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium enters the principal cell across the basolateral membrane via the Na+-K+-ATPase pump; &nbsp;it is then secreted into the lumen down a favorable electrochemical gradient through K+ channels in the luminal membrane (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/3,16,17\">",
"     3,16,17",
"    </a>",
"    ]. This final step, K+ movement from the cell into the lumen, appears to be passive [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] and, therefore, is primarily governed by those factors that affect passive transport:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The concentration gradient across the luminal membrane, which is equal to the difference between the cell and tubular fluid K+ concentrations. Although the total cell K+ concentration is about 140 to 150",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      ionic interactions with multivalent anions within the cell lower the random movement or activity of cytosolic K+ to about 80 to 90",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. This value is still well above that in the tubular lumen; it is not clear, however, if all or only part of this K+ represents the transport pool that is available for K+ secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/20\">",
"       20",
"      </a>",
"      ]. Regardless of its exact composition, the size of this pool is not constant, appropriately increasing after a K+ load and decreasing with K+ depletion [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/20\">",
"       20",
"      </a>",
"      ]. The plasma K+ concentration and aldosterone appear to be the prime determinants of this response.",
"     </li>",
"     <li>",
"      The electrical gradient, which is primarily generated by the reabsorption of Na+ through Na+ channels in the luminal membrane.",
"     </li>",
"     <li>",
"      The K+ permeability of the luminal membrane, which is a reflection of the number of open K+ channels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As will be seen, aldosterone and the plasma K+ concentration, acting in concert, are the major physiologic regulators of K+ secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/21\">",
"     21",
"    </a>",
"    ]. The flow rate to the distal nephron and the potential difference generated by Na+ reabsorption also are important, but they usually have a permissive rather than a regulatory effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ALDOSTERONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone plays a major role in K+ homeostasis by augmenting K+ secretion in the principal cells in the cortical collecting tubule, and in adjacent cells in the connecting segment and the outer part of the medullary collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. After a K+ load, for example, aldosterone secretion is directly enhanced, thereby promoting the excretion of the excess K+ in the urine. This response is very efficient, since a rise in the plasma K+ concentration of as little as 0.1 to 0.2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    can induce a significant elevation in aldosterone release [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/27\">",
"     27",
"    </a>",
"    ]. Conversely, secretion of this hormone is reduced with K+ depletion, a response that tends to preserve K+ balance by minimizing further urinary losses.",
"   </p>",
"   <p>",
"    Aldosterone appears to result in stimulation of each of the major transport steps depicted in Fig. 12-9: it increases the number of open Na+ and K+ channels in the luminal membrane; and it enhances the activity of the Na+-K+-ATPase pump in the basolateral membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    .) The rise in luminal Na+ permeability is the earliest change; it promotes Na+ entry into the cell, and this Na+ is then returned to the systemic circulation by the Na+-K+-ATPase pump. These changes can enhance K+ secretion by two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The transport of Na+ out of the cell by the Na+-K+-ATPase pump also results in K+ movement into the cell, thereby increasing the size of the K+ transport pool [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The reabsorption of cationic Na+ makes the lumen relatively electronegative, thereby increasing the electrical gradient favoring K+ secretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any persistent increase in K+ secretion must be accompanied by enhanced Na+-K+-ATPase activity; if this did not occur; there would be eventual depletion of cell K+ stores. It is of interest in this regard that the ratio of Na+ reabsorption to K+ secretion in the cortical collecting tubule is 3:2, similar to the stoichiometry of the Na+-K+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/31\">",
"     31",
"    </a>",
"    ]. This observation suggests the following sequence: the Na+-K+-ATPase pump transports reabsorbed Na+ out of the cell in exchange for extracellular K+; most of this K+ is then secreted into the lumen, rather than leaking back out across the basolateral membrane and being returned to the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primacy of the Na+ reabsorptive effect is also suggested by the response to the diuretic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    . This agent closes the luminal Na+ channels and at least transiently prevents the aldosterone-induced increases in K+ secretion, luminal K+ permeability, and Na+-K+-ATPase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/29,32\">",
"     29,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other hormones can also enhance distal K+ secretion, including antidiuretic hormone (ADH), which appears to increase the number of luminal K+ channels [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Although ADH is not a primary regulator of K+ excretion, the elevation in luminal K+ permeability may be physiologically important. It can counteract the associated reduction in distal flow due to ADH-induced water reabsorption, thereby preventing an undesired decrease in K+ excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PLASMA POTASSIUM CONCENTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma K+ concentration can directly affect K+ excretion, independent of other factors such as aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/35\">",
"     35",
"    </a>",
"    ]. An example of this relationship is illustrated in Fig. 12-10. Dogs were adrenalectomized, given aldosterone replacement at different doses, and then studied at different levels of K+ intake. As intake was increased, there was a gradual elevation in the plasma K+ concentration. When aldosterone replacement was at a normal level (50",
"    <span class=\"nowrap\">",
"     &micro;g/day,",
"    </span>",
"    middle curve), urinary K+ excretion remained at low levels until the plasma K+ concentration exceeded 4.2",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    At this point, K+ excretion increased markedly in an attempt to maintain K+ balance. This presumably reflected a direct effect of the plasma K+ concentration, since aldosterone levels, Na+ intake, and the urine output were relatively constant.",
"   </p>",
"   <p>",
"    In intact animals, however, aldosterone secretion will rise after a K+ load, resulting in even more rapid excretion of K+ (left curve, Figure 4). The kidney is normally so efficient in excreting excess K+ that chronic hyperkalemia cannot occur unless there is an associated defect in urinary K+ excretion.",
"   </p>",
"   <p>",
"    Studies in adrenalectomized animals have also elucidated the mechanism by which the plasma K+ concentration affects distal K+ secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Potassium alone replicates all of the changes in the principal cells that are induced by aldosterone: it increases Na+ reabsorption and K+ secretion; luminal membrane permeability to Na+ and K+ (by increasing the number of open channels) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/16\">",
"     16",
"    </a>",
"    ]; and the activity of the Na+-K+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/36\">",
"     36",
"    </a>",
"    ]. How these changes occur is not known. They are, however, less prominent than those seen when a K+ load is appropriately accompanied by a rise in aldosterone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The experiments in Figure 5 (",
"    <a class=\"graphic graphic_figure graphicRef82385 \" href=\"UTD.htm?34/32/35341\">",
"     figure 5",
"    </a>",
"    ) also demonstrate the effect of chronic changes in aldosterone secretion on the steady state plasma K+ concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/21\">",
"     21",
"    </a>",
"    ]. If K+ intake and excretion are normal at 50",
"    <span class=\"nowrap\">",
"     meq/day,",
"    </span>",
"    the plasma K+ concentration will be approximately 4.3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in dogs receiving physiologic levels of aldosterone (50",
"    <span class=\"nowrap\">",
"     &micro;g/day),",
"    </span>",
"    3.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with hyperaldosteronism (250",
"    <span class=\"nowrap\">",
"     &micro;g/day),",
"    </span>",
"    and 5.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with hypoaldosteronism (20",
"    <span class=\"nowrap\">",
"     &micro;g/day).",
"    </span>",
"    When less aldosterone is available, for example, urinary K+ excretion becomes less efficient; as a result, a higher plasma K+ concentration is required to establish a new steady state in which intake again equals excretion. Thus, hypoaldosteronism is associated with hyperkalemia, whereas primary aldosteronism enhances urinary K+ loss, often leading to a fall in the plasma K+ concentration (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DISTAL FLOW RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing distal flow rate is another potentially important stimulus of distal K+ secretion (",
"    <a class=\"graphic graphic_figure graphicRef57184 \" href=\"UTD.htm?25/34/26157\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. This response is most prominent in the presence of a high-K+ diet, since the concurrent elevations in aldosterone release and the plasma K+ concentration produce a high basal level of K+ secretion. In comparison, K+ depletion can lead to net reabsorption, not secretion, in the distal nephron [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/7\">",
"     7",
"    </a>",
"    ]. It is not surprising, therefore, that distal flow has little or no effect on K+ secretion in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which distal flow affects renal K+ handling is incompletely understood, but changes in the tubular fluid K+ concentration appear to play an important role [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/40\">",
"     40",
"    </a>",
"    ]. As described previously, almost all of the filtered K+ is reabsorbed in the proximal tubule and loop of Henle; as a result, the K+ concentration in the fluid entering the distal nephron may be less than 1",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    The combination of K+ secretion and, if ADH is present, water reabsorption in the cortical collecting tubule raises the tubular fluid K+ concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/40\">",
"     40",
"    </a>",
"    ]. Increasing distal flow washes the secreted K+ away and replaces it with relatively K+-free fluid from the more proximal segments. Thus, the K+ concentration in the lumen is kept at a relatively low level, maintaining a favorable gradient for continued K+ secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is that the tubular fluid K+ concentration remains nearly constant within the physiologic range of flow rate; increasing flow results in more K+ being secreted without any elevation in the luminal K+ concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/41\">",
"     41",
"    </a>",
"    ]. There may, however, be a rise in the tubular fluid K+ concentration when distal flow is substantially diminished due, for example, to volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/41\">",
"     41",
"    </a>",
"    ]. In this setting, the high luminal concentration (due to less washout of secreted K+) and the low urine flow lead to a reduction in the absolute rate of K+ secretion.",
"   </p>",
"   <p>",
"    The flow-dependence of K+ secretion may also be related to changes in the delivery of Na+ to the distal secretory site [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/41\">",
"     41",
"    </a>",
"    ]. Increased distal flow is generally associated with enhanced Na+ delivery to and reabsorption in the cortical collecting tubule. As noted above, this elevation in Na+ transport has two effects that favor K+ secretion: (1) the entry of Na+ into the cells through its channels in the luminal membrane makes the lumen relatively electronegative, creating an electrical gradient that favors the movement of K+ from the cells into the lumen (see below); and (2) the subsequent transport of this Na+ out of the cell by the Na+-K+-ATPase pump in the basolateral membrane results in the entry of new K+ into the cells, thereby providing more K+ for continued secretion*. Thus, the flow-dependence of K+ secretion is probably mediated by the parallel changes in both water [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/40,42\">",
"     40,42",
"    </a>",
"    ] and Na+ delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physiologic role",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between K+ secretion and distal flow rate plays an important role in allowing aldosterone to regulate Na+ and K+ balance independently [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/21\">",
"     21",
"    </a>",
"    ] and, as mentioned above, in allowing ADH to regulate H2O balance without affecting the secretion of K+ [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. As an example, a Na+ load expands the extracellular volume, resulting in a reduction in the secretion of renin and therefore that of aldosterone. Although the latter change promotes the excretion of the excess Na+ (by decreasing cortical collecting tubule Na+ reabsorption), it should also lead to K+ retention and hyperkalemia. This does not happen, however, since volume expansion tends to increase the GFR and to diminish proximal Na+ reabsorption, both of which augment distal flow rate. The enhanced flow counteracts the fall in aldosterone release, resulting in little or no change in K+ excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/21,43\">",
"     21,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome will be different if a Na+ load is administered in the presence of nonsuppressible aldosterone secretion, as occurs in patients with primary hyperaldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/44\">",
"     44",
"    </a>",
"    ]. In this setting, the combination of increased distal flow and normal or elevated aldosterone levels leads to enhanced urinary K+ excretion and a reduction in the plasma K+ concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These changes are reversed with volume depletion, as the combination of increased aldosterone release and reduced distal flow allows Na+ to be conserved without substantially affecting K+ balance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/21,46\">",
"     21,46",
"    </a>",
"    ]. These observations explain why untreated patients with heart failure or cirrhosis are typically normokalemic, despite the common presence of secondary hyperaldosteronism and high ADH levels. If, however, distal flow is increased, then inappropriate K+ wasting is likely to ensue. This appears to be the major mechanism by which the loop and thiazide diuretics induce hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/47\">",
"     47",
"    </a>",
"    ]. These agents enhance distal delivery by diminishing Na+ and water reabsorption in the loop of Henle and distal tubule, respectively. They also tend to stimulate aldosterone secretion, because of the concomitant reduction in extracellular volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H27627359#H27627359\">",
"     \"Causes of hypokalemia\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SODIUM REABSORPTION AND THE TRANSEPITHELIAL POTENTIAL DIFFERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since K+ is a charged particle, its secretion is importantly affected by the transepithelial potential difference across the tubular cell. The normal potential difference in the K+-secreting cells is approximately -15 to -50 mV (lumen negative) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/31,48,49\">",
"     31,48,49",
"    </a>",
"    ]. This potential is generated by the transport of Na+ from the lumen into the peritubular capillary (",
"    <a class=\"graphic graphic_figure graphicRef77973 \" href=\"UTD.htm?31/35/32317\">",
"     figure 7",
"    </a>",
"    ). Since Na+ is positively charged, its reabsorption makes the lumen relatively electronegative. Cl- is passively reabsorbed via the paracellular route down this electrical gradient; there is, however, a finite time lag, and it is this delay that is responsible for the observed potential difference.",
"   </p>",
"   <p>",
"    The importance of Na+ in the generation of this potential can be illustrated by the response to replacing luminal Na+ with a nonreabsorbable cation, such as choline+ [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/48\">",
"     48",
"    </a>",
"    ]. In this setting, the potential difference falls to zero (",
"    <a class=\"graphic graphic_figure graphicRef77973 \" href=\"UTD.htm?31/35/32317\">",
"     figure 7",
"    </a>",
"    ). On the other hand, replacing luminal Cl- &nbsp;with a poorly reabsorbed anion, such as SO42-, increases the anion delay and augments the potential difference.",
"   </p>",
"   <p>",
"    The central role of the Na+-generated potential difference on K+ secretion can be illustrated by the response to the diuretic,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/20,47\">",
"     20,47",
"    </a>",
"    ]. This agent impairs the entry of luminal Na+ into the cells of the distal nephron by closing the Na+ channels in the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/50\">",
"     50",
"    </a>",
"    ]. The net effect is diminished Na+ reabsorption and a reduction in the transepithelial potential difference, even in the presence of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/20,29,47\">",
"     20,29,47",
"    </a>",
"    ]. There is also a marked fall in K+ secretion; it is likely that this effect is due to the decrease in potential difference, since amiloride has no known direct influence on K+ handling [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stimulatory effect of Na+ transport on K+ secretion is more prominent if Na+ is delivered with an anion other than Cl- that is nonreabsorbable. In this setting, there will be less Cl- available for reabsorption to dissipate the lumen-negative electrical gradient created by Na+ entry into the cell. As an example, a volume-depleted subject has a strong stimulus to Na+ reabsorption in the cortical collecting tubule that is mediated by aldosterone. In this situation, the administration of Na2SO4 results in Na+ reabsorption without SO42- and, consequently, increases in the potential difference (",
"    <a class=\"graphic graphic_figure graphicRef77973 \" href=\"UTD.htm?31/35/32317\">",
"     figure 7",
"    </a>",
"    ) and K+ secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/49,51,52\">",
"     49,51,52",
"    </a>",
"    ]. In contrast, if Na+ balance and therefore both Cl- delivery and aldosterone secretion are normal, there is no stimulus to retain the excess Na+ and Na2SO4 is excreted with only a small elevation in K+ secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A clinical example of this phenomenon may follow the intravenous administration of the antibiotic carbenicillin, which contains 4.7 meq of Na+ per gram. Thirty grams of this compound contains approximately 140 meq of the carbenicillin anion; the presence of this nonreabsorbable anion in the tubular fluid can, in some patients, lead to enhanced urinary K+ loss and hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in humans suggest that, in addition to volume status, the nonreabsorbable anion itself may be a determinant of the effect on K+ secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/52\">",
"     52",
"    </a>",
"    ]. Although the ability of sulfate to enhance K+ loss is minimized by euvolemia, HCO3- is still able to promote K+ secretion in this setting. How this might occur is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EXTRACELLULAR PH",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, changes in the extracellular pH produce reciprocal H+ and K+ shifts between the cells and the ECF. As a result, K+ tends to move into cells with alkalemia and out of cells with acidemia. These changes in the cell K+ concentration will tend to reduce K+ secretion in acidemia and to increase K+ secretion in alkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These pH-induced effects, however, are transient and are frequently overridden by concurrent variations in other factors that affect K+ handling [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In proximal renal tubular acidosis, for example, proximal HCO3- reabsorption is impaired. As a result, there is increased delivery of Na+, the poorly reabsorbable anion HCO3-, and water to the distal secretory site. These changes overcome the direct effect of acidosis, and K+ loss ensues [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. A similar sequence occurs in diabetic ketoacidosis, where Na+ and water are delivered to the distal nephron with the ketoacid anions, &szlig;-hydroxybutyrate and acetoacetate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RENAL RESPONSE TO POTASSIUM DEPLETION AND POTASSIUM LOADING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regulation of K+ excretion can be summarized by reviewing the renal responses to changes in K+ balance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Potassium depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;K+ excretion, for example, appropriately falls with K+ depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/4,7,62\">",
"     4,7,62",
"    </a>",
"    ]. This response is initially mediated by diminished release of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/62\">",
"     62",
"    </a>",
"    ], which represents a direct effect of K+ on the adrenal zona glomerulosa cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/63\">",
"     63",
"    </a>",
"    ]. Within several days, however, a decrease in the cell K+ concentration in the distal nephron probably assumes primary importance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/62\">",
"     62",
"    </a>",
"    ]. At this time, neither the administration of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/62,64\">",
"     62,64",
"    </a>",
"    ] nor increasing distal flow rate (",
"    <a class=\"graphic graphic_figure graphicRef57184 \" href=\"UTD.htm?25/34/26157\">",
"     figure 6",
"    </a>",
"    ) substantially enhances urinary K+ loss.",
"   </p>",
"   <p>",
"    The fall in K+ excretion in this setting is due both to reduced secretion and to active K+ reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. The latter process occurs in the intercalated cells in the cortex and outer medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and appears to be mediated by a luminal H+-K+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. The activity of this pump, which reabsorbs K+ and secretes H+, &nbsp;increases with K+ depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. This change is associated with an elevation in luminal membrane area in the intercalated cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], due at least in part to insertion of new H+-K+-ATPase pumps in the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is that K+ excretion can be lowered to 15 to 25",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    with a total K+ deficit of 50 to 150 meq, and to 5 to 15",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    with more marked K+ loss [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/65\">",
"     65",
"    </a>",
"    ]. The inability to conserve K+ more efficiently may be related to relatively more water than K+ reabsorption and persistent K+ secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Potassium loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary K+ excretion increases after a K+ load [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/3\">",
"     3",
"    </a>",
"    ]. This response is so efficient that normal subjects can maintain K+ balance even if K+ intake is slowly increased from the normal level of 60 to 80",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    up to 500",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    or more [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. This response is mediated both by aldosterone and a rise in the plasma K+ concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/21,67\">",
"     21,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability to handle what might be a lethal K+ load if given acutely is called K+ adaptation and is due primarily to more rapid K+ excretion in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/68\">",
"     68",
"    </a>",
"    ]. Early adaptation can be induced by a single normal meal. As an example, rats fed a meal containing K+ were better able to excrete an intravenous K+ load several hours later than fasted rats; more rapid urinary excretion meant that there was a smaller elevation in the plasma K+ concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to increased urinary excretion, two other factors, both of which are promoted by aldosterone, also may contribute to more chronic adaptation: (1) enhanced K+ entry into extrarenal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/70,71\">",
"     70,71",
"    </a>",
"    ], the importance of which is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/72\">",
"     72",
"    </a>",
"    ]; and (2) increased gastrointestinal losses due to colonic secretion of K+ [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in urinary K+ excretion during adaptation is due to enhanced K+ secretion throughout the late distal nephron, including the short connecting segment, and the principal cells in the cortical and outer medullary collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/7,25,37,38,75\">",
"     7,25,37,38,75",
"    </a>",
"    ]. The efficacy of this response is illustrated in Figure 4 (",
"    <a class=\"graphic graphic_figure graphicRef67129 \" href=\"UTD.htm?17/18/17709\">",
"     figure 8",
"    </a>",
"    ) which shows that distal K+ secretion at a given plasma K+ concentration is two to four times higher in K+-adapted rats [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition to increased secretion, decreased reabsorption in the intercalated cells (mediated by a decrease in activity of the K+-ATPase pump) also may contribute to the kaliuresis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both increased secretion of aldosterone and a small elevation in the plasma K+ concentration are required for the complete expression of this response [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/25,38\">",
"     25,38",
"    </a>",
"    ]. They act in part by enhancing Na+-K+-ATPase activity in these distal segments [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/37,76\">",
"     37,76",
"    </a>",
"    ], either directly or by increasing the entry of luminal Na+ into the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/28,32,36\">",
"     28,32,36",
"    </a>",
"    ]. The morphologic correlate of this increase in Na+-K+-ATPase activity is a marked increase in the area of the basolateral membrane, the site at which the Na+-K+-ATPase pumps are inserted [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/1\">",
"     1",
"    </a>",
"    ]. This morphologic change begins within the first day of a high K+ intake and does not reach a plateau until two weeks.",
"   </p>",
"   <p>",
"    The role of these parameters in humans can be illustrated by the response to chronic K+ loading (400",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    in normal subjects (",
"    <a class=\"graphic graphic_figure graphicRef50808 \" href=\"UTD.htm?18/26/18862\">",
"     figure 9",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/67\">",
"     67",
"    </a>",
"    ]. The plasma K+ concentration rose from 3.8 to 4.8",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and the plasma aldosterone concentration increased 2.5 fold in the first two days. By 20 days, however, both the plasma K+ concentration (4.2",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and the plasma aldosterone concentration had partially returned toward baseline levels, even though urinary K+ excretion remained very high.",
"   </p>",
"   <p>",
"    The increased efficiency of K+ secretion at this time was probably related to the hyperkalemia-induced rise in Na+-K+-ATPase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/67\">",
"     67",
"    </a>",
"    ]. Indirect evidence in support of this hypothesis was the observation that discontinuing the K+ load led to transient Na+ retention that could have reflected the time required for distal Na+-K+-ATPase activity to fall back to normal.",
"   </p>",
"   <p>",
"    The major clinical example of K+ adaptation occurs in chronic renal failure, in which the combination of a constant K+ intake and fewer functioning nephrons requires an increase in K+ excretion per nephron [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. This allows K+ balance to be maintained even in advanced disease, as long as intake is not excessive, the urine output and therefore the distal flow rate are adequate, and aldosterone secretion can be appropriately increased [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in experimental animals with renal failure have shown that Na+-K+-ATPase activity in the distal nephron is elevated, an expected correlate of enhanced K+ secretion per nephron [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/81\">",
"     81",
"    </a>",
"    ]. However, this elevation in pump activity is seen only when K+ intake is normal, not when intake is restricted in proportion to the fall in GFR, a setting in which increased K+ excretion per nephron is not required [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/81\">",
"     81",
"    </a>",
"    ]. This finding suggests that the rise in Na+-K+-ATPase activity is appropriate and specific, not incidentally induced by renal insufficiency.",
"   </p>",
"   <p>",
"    Enhanced colonic secretion of K+ also may play an important role in advanced renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/73,82\">",
"     73,82",
"    </a>",
"    ]. It has been estimated that increased stool losses may account for the excretion of as much as 30 to 50 percent of dietary K+ in patients with end-stage renal failure on chronic dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maintenance of a normal plasma K+ concentration is dependent upon the ability of K+ to enter the cells, where it achieves high concentrations, and upon the urinary excretion of net dietary intake. After a K+ load, most of the extra K+ is initially taken up by the cells, a response that is facilitated by basal levels of catecholamines and insulin. This cell uptake minimizes the increase in the plasma K+ concentration, pending the excretion of the excess K+ in the urine.",
"   </p>",
"   <p>",
"    Urinary K+ excretion is largely a function of secretion in the distal nephron, primarily in the principal cells in the cortical collecting tubule. The main factors modulating this process are aldosterone and the plasma K+ concentration itself. Distal flow rate and the transepithelial potential difference (which is generated primarily by Na+ reabsorption) play a more permissive role: they do not change directly with K+ balance, but relatively normal values are required for adequate K+ secretion.",
"   </p>",
"   <p>",
"    Understanding these principles can simplify the approach to patients with disorders of K+ balance. Chronic hyperkalemia, for example, must be associated with a defect in distal K+ secretion, since the adaptation response would normally permit excretion of the excess K+ (",
"    <a class=\"graphic graphic_figure graphicRef50808 \" href=\"UTD.htm?18/26/18862\">",
"     figure 9",
"    </a>",
"    ). From the preceding discussion, the two major mechanisms by which K+ secretion might be impaired are hypoaldosteronism and decreased distal flow (due to marked volume depletion or advanced renal failure). These conditions therefore constitute most of the differential diagnosis of persistent hyperkalemia. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary K+ wasting and hypokalemia, on the other hand, are due to activation of the distal secretory process. This most often occurs with hyperaldosteronism (as long as distal flow is maintained), increased distal flow (as long as aldosterone secretion is normal or elevated, as with diuretic therapy), or with the delivery of Na+ to the distal nephron with a nonreabsorbable anion (as is seen in ketoacidosis or proximal renal tubular acidosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11657/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15766?source=see_link\">",
"     \"Chapter 13A: Meaning of urine electrolytes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/1\">",
"      Stanton BA. Renal potassium transport: morphological and functional adaptations. Am J Physiol 1989; 257:R989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/2\">",
"      Greger R, G&ouml;gelein H. Role of K+ conductive pathways in the nephron. Kidney Int 1987; 31:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/3\">",
"      Giebisch G, Wang W. Potassium transport: from clearance to channels and pumps. Kidney Int 1996; 49:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/4\">",
"      Malnic G, Klose RM, Giebisch G. Micropuncture study of distal tubular potassium and sodium transport in rat nephron. Am J Physiol 1966; 211:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/5\">",
"      Kaufman JS, Hamburger RJ. Passive potassium transport in the proximal convoluted tubule. Am J Physiol 1985; 248:F228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/6\">",
"      Diezi J, Michoud P, Aceves J, Giebisch G. Micropuncture study of electrolyte transport across papillary collecting duct of the rat. Am J Physiol 1973; 224:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/7\">",
"      Stanton BA, Biemesderfer D, Wade JB, Giebisch G. Structural and functional study of the rat distal nephron: effects of potassium adaptation and depletion. Kidney Int 1981; 19:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/8\">",
"      Stetson DL, Wade JB, Giebisch G. Morphologic alterations in the rat medullary collecting duct following potassium depletion. Kidney Int 1980; 17:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/9\">",
"      Garg LC, Narang N. Ouabain-insensitive K-adenosine triphosphatase in distal nephron segments of the rabbit. J Clin Invest 1988; 81:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/10\">",
"      Wingo CS, Madsen KM, Smolka A, Tisher CC. H-K-ATPase immunoreactivity in cortical and outer medullary collecting duct. Kidney Int 1990; 38:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/11\">",
"      Kraut JA, Hiura J, Besancon M, et al. Effect of hypokalemia on the abundance of HK alpha 1 and HK alpha 2 protein in the rat kidney. Am J Physiol 1997; 272:F744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/12\">",
"      Okusa MD, Unwin RJ, Vel&aacute;zquez H, et al. Active potassium absorption by the renal distal tubule. Am J Physiol 1992; 262:F488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/13\">",
"      Garg LC, Narang N. Suppression of ouabain-insensitive K-ATPase activity in rabbit nephron segments during chronic hyperkalemia. Renal Physiol Biochem, 1989; 12:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/14\">",
"      Jamison RL. Potassium recycling. Kidney Int 1987; 31:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/15\">",
"      Milanes CL, Jamison RL. Effect of acute potassium load on reabsorption in Henle's loop in chronic renal failure in the rat. Kidney Int 1985; 27:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/16\">",
"      Wang WH, Schwab A, Giebisch G. Regulation of small-conductance K+ channel in apical membrane of rat cortical collecting tubule. Am J Physiol 1990; 259:F494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/17\">",
"      Wang WH. View of K+ secretion through the apical K channel of cortical collecting duct. Kidney Int 1995; 48:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/18\">",
"      Civan MM. Potassium activities in epithelia. Fed Proc 1980; 39:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/19\">",
"      Adam WR, Koretsky AP, Weiner MW. Potassium adaptation: 39K-NMR evidence for intracellular compartmentalization of K+. Am J Physiol 1988; 254:F401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/20\">",
"      Garcia-Filho E, Malnic G, Giebisch G. Effects of changes in electrical potential difference on tubular potassium transport. Am J Physiol 1980; 238:F235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/21\">",
"      Young DB. Quantitative analysis of aldosterone's role in potassium regulation. Am J Physiol, 1988; 255:F811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/22\">",
"      Stanton BA. Regulation of Na+ and K+ transport by mineralocorticoids. Semin Nephrol 1987; 7:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/23\">",
"      Stokes JB, Ingram MJ, Williams AD, Ingram D. Heterogeneity of the rabbit collecting tubule: localization of mineralocorticoid hormone action to the cortical portion. Kidney Int 1981; 20:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/24\">",
"      Muto S, Giebisch G, Sansom S. Effects of adrenalectomy on CCD: evidence for differential response of two cell types. Am J Physiol 1987; 253:F742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/25\">",
"      Kashgarian M, Ardito T, Hirsch DJ, Hayslett JP. Response of collecting tubule cells to aldosterone and potassium loading. Am J Physiol 1987; 253:F8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/26\">",
"      Rabinowitz L. Aldosterone and potassium homeostasis. Kidney Int 1996; 49:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/27\">",
"      Himathongkam T, Dluhy RG, Williams GH. Potassim-aldosterone-renin interrelationships. J Clin Endocrinol Metab 1975; 41:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/28\">",
"      Sansom SC, O'Neil RG. Mineralocorticoid regulation of apical cell membrane Na+ and K+ transport of the cortical collecting duct. Am J Physiol 1985; 248:F858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/29\">",
"      Sansom S, Muto S, Giebisch G. Na-dependent effects of DOCA on cellular transport properties of CCDs from ADX rabbits. Am J Physiol 1987; 253:F753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/30\">",
"      Clausen T, Everts ME. Regulation of the Na,K-pump in skeletal muscle. Kidney Int 1989; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/31\">",
"      Stokes JB. Sodium and potassium transport by the collecting duct. Kidney Int 1990; 38:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/32\">",
"      Petty KJ, Kokko JP, Marver D. Secondary effect of aldosterone on Na-KATPase activity in the rabbit cortical collecting tubule. J Clin Invest 1981; 68:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/33\">",
"      Cassola AC, Giebisch G, Wang W. Vasopressin increases density of apical low-conductance K+ channels in rat CCD. Am J Physiol 1993; 264:F502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/34\">",
"      Field MJ, Stanton BA, Giebisch GH. Influence of ADH on renal potassium handling: a micropuncture and microperfusion study. Kidney Int 1984; 25:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/35\">",
"      Young DB, Paulsen AW. Interrelated effects of aldosterone and plasma potassium on potassium excretion. Am J Physiol 1983; 244:F28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/36\">",
"      Muto S, Sansom S, Giebisch G. Effects of a high potassium diet on electrical properties of cortical collecting ducts from adrenalectomized rabbits. J Clin Invest 1988; 81:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/37\">",
"      Garg LC, Narang N. Renal adaptation to potassium in the adrenalectomized rabbit. Role of distal tubular sodium-potassium adenosine triphosphatase. J Clin Invest 1985; 76:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/38\">",
"      Stanton B, Pan L, Deetjen H, et al. Independent effects of aldosterone and potassium on induction of potassium adaptation in rat kidney. J Clin Invest 1987; 79:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/39\">",
"      Khuri RN, Strieder WN, Giebisch G. Effects of flow rate and potassium intake on distal tubular potassium transfer. Am J Physiol 1975; 228:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/40\">",
"      Good DW, Wright FS. Luminal influences on potassium secretion: sodium concentration and fluid flow rate. Am J Physiol 1979; 236:F192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/41\">",
"      Malnic G, Berliner RW, Giebisch G. Flow dependence of K+ secretion in cortical distal tubules of the rat. Am J Physiol 1989; 256:F932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/42\">",
"      Good DW, Vel&aacute;zquez H, Wright FS. Luminal influences on potassium secretion: low sodium concentration. Am J Physiol 1984; 246:F609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/43\">",
"      Young DB, McCaa RE. Role of the renin-angiotensin system in potassium control. Am J Physiol 1980; 238:R359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/44\">",
"      George JM, Wright L, Bell NH, Bartter FC. The syndrome of primary aldosteronism. Am J Med 1970; 48:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/45\">",
"      Young DB, Jackson TE, Tipayamontri U, Scott RC. Effects of sodium intake on steady-state potassium excretion. Am J Physiol 1984; 246:F772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/46\">",
"      SELDIN DW, WELT LG, CORT JH. The role of sodium salts and adrenal steroids in the production of hypokalemic alkalosis. Yale J Biol Med 1956; 29:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/47\">",
"      Duarte CG, Chomety F, Giebisch G. Effect of amiloride, ouabain, and furosemide on distal tubular function in the rat. Am J Physiol 1971; 221:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/48\">",
"      Giebisch G, Malnic G, Klose RM, Windhager EE. Effect of ionic substitutions on distal potential differences in rat kidney. Am J Physiol 1966; 211:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/49\">",
"      Vel&aacute;zquez H, Wright FS, Good DW. Luminal influences on potassium secretion: chloride replacement with sulfate. Am J Physiol 1982; 242:F46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/50\">",
"      Benos DJ. Amiloride: a molecular probe of sodium transport in tissues and cells. Am J Physiol 1982; 242:C131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/51\">",
"      SCHWARTZ WB, JENSON RL, RELMAN AS. Acidification of the urine and increased ammonium excretion without change in acid-base equilibrium: sodium reabsorption as a stimulus to the acidifying process. J Clin Invest 1955; 34:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/52\">",
"      Carlisle EJ, Donnelly SM, Ethier JH, et al. Modulation of the secretion of potassium by accompanying anions in humans. Kidney Int 1991; 39:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/53\">",
"      Lipner HI, Ruzany F, Dasgupta M, et al. The behavior of carbenicillin as a nonreabsorbable anion. J Lab Clin Med 1975; 86:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/54\">",
"      Klastersky J, Vanderklen B, Daneau D, Mathiew M. Carbenicillin and hypokalemia. Ann Intern Med 1973; 78:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/55\">",
"      Malnic G, De Mello Aires M, Giebisch G. Potassium transport across renal distal tubules during acid-base disturbances. Am J Physiol 1971; 221:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/56\">",
"      BARKER ES, SINGER RB, ELKINTON JR, CLARK JK. The renal response in man to acute experimental respiratory alkalosis and acidosis. J Clin Invest 1957; 36:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/57\">",
"      Stanton BA, Giebisch G. Effects of pH on potassium transport by renal distal tubule. Am J Physiol 1982; 242:F544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/58\">",
"      Gennari FJ, Cohen JJ. Role of the kidney in potassium homeostasis: lessons from acid-base disturbances. Kidney Int 1975; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/59\">",
"      Scandling JD, Ornt DB. Mechanism of potassium depletion during chronic metabolic acidosis in the rat. Am J Physiol 1987; 252:F122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/60\">",
"      Sebastian A, McSherry E, Morris RC Jr. Renal potassium wasting in renal tubular acidosis (RTA): its occurrence in types 1 and 2 RTA despite sustained correction of systemic acidosis. J Clin Invest 1971; 50:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/61\">",
"      Sebastian A, McSherry E, Morris RC Jr. On the mechanism of renal potassium wasting in renal tubular acidosis associated with the Fanconi syndrome (type 2 RTA). J Clin Invest 1971; 50:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/62\">",
"      Linas SL, Peterson LN, Anderson RJ, et al. Mechanism of renal potassium conservation in the rat. Kidney Int 1979; 15:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/63\">",
"      Aguilera G, Catt KJ. Loci of action of regulators of aldosterone biosynthesis in isolated glomerulosa cells. Endocrinology 1978; 104:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/64\">",
"      Mujais SK, Chen Y, Nora NA. Discordant aspects of aldosterone resistance in potassium depletion. Am J Physiol 1992; 262:F972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/65\">",
"      SQUIRES RD, HUTH EJ. Experimental potassium depletion in normal human subjects. I. Relation of ionic intakes to the renal conservation of potassium. J Clin Invest 1959; 38:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/66\">",
"      Talbott JH, Schwab RS. Recent advances in the biochemistry and therapeusis of potassium salts. N Engl J Med 1940; 222:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/67\">",
"      Rabelink TJ, Koomans HA, Hen&eacute; RJ, Dorhout Mees EJ. Early and late adjustment to potassium loading in humans. Kidney Int 1990; 38:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/68\">",
"      Hayslett JP, Binder HJ. Mechanism of potassium adaptation. Am J Physiol 1982; 243:F103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/69\">",
"      Jackson CA. Rapid renal potassium adaptation in rats. Am J Physiol 1992; 263:F1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/70\">",
"      Alexander EA, Levinsky NG. An extrarenal mechanism of potassium adaptation. J Clin Invest 1968; 47:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/71\">",
"      Blachley JD, Crider BP, Johnson JH. Extrarenal potassium adaptation: role of skeletal muscle. Am J Physiol 1986; 251:F313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/72\">",
"      Spital A, Sterns RH. Paradoxical potassium depletion: a renal mechanism for extrarenal potassium adaptation. Kidney Int 1986; 30:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/73\">",
"      Foster ES, Jones WJ, Hayslett JP, Binder HJ. Role of aldosterone and dietary potassium in potassium adaptation in the distal colon of the rat. Gastroenterology 1985; 88:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/74\">",
"      Sweiry JH, Binder HJ. Characterization of aldosterone-induced potassium secretion in rat distal colon. J Clin Invest 1989; 83:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/75\">",
"      Schon DA, Backman KA, Hayslett JP. Role of the medullary collecting duct in potassium excretion in potassium-adapted animals. Kidney Int 1981; 20:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/76\">",
"      Silva P, Hayslett JP, Epstein FH. The role of Na-K-activated adenosine triphosphatase in potassium adaptation. Stimulation of enzymatic activity by potassium loading. J Clin Invest 1973; 52:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/77\">",
"      Schultze RG, Taggart DD, Shapiro H, et al. On the adaptation in potassium excretion associated with nephron reduction in the dog. J Clin Invest 1971; 50:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/78\">",
"      Bourgoignie JJ, Kaplan M, Pincus J, et al. Renal handling of potassium in dogs with chronic renal insufficiency. Kidney Int 1981; 20:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/79\">",
"      Gonick HC, Kleeman CR, Rubini ME, Maxwell MH. Functional impairment in chronic renal disease. 3. Studies of potassium excretion. Am J Med Sci 1971; 261:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/80\">",
"      Schambelan M, Sebastian A, Biglieri EG. Prevalence, pathogenesis, and functional significance of aldosterone deficiency in hyperkalemic patients with chronic renal insufficiency. Kidney Int 1980; 17:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/81\">",
"      Schon DA, Silva P, Hayslett JP. Mechanism of potassium excretion in renal insufficiency. Am J Physiol 1974; 227:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/82\">",
"      Bastl C, Hayslett JP, Binder HJ. Increased large intestinal secretion of potassium in renal insufficiency. Kidney Int 1977; 12:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/83\">",
"      Brown RS. Extrarenal potassium homeostasis. Kidney Int 1986; 30:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11657/abstract/84\">",
"      HAYES CP Jr, ROBINSON RR. FECAL POTASSIUM EXCRETION IN PATIENTS ON CHRONIC INTERMITTENT HEMODIALYSIS. Trans Am Soc Artif Intern Organs 1965; 11:242.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7264 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11657=[""].join("\n");
var outline_f11_24_11657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SEGMENTAL POTASSIUM HANDLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Medullary recycling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CELL MODEL FOR POTASSIUM SECRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ALDOSTERONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PLASMA POTASSIUM CONCENTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DISTAL FLOW RATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physiologic role",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SODIUM REABSORPTION AND THE TRANSEPITHELIAL POTENTIAL DIFFERENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EXTRACELLULAR PH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RENAL RESPONSE TO POTASSIUM DEPLETION AND POTASSIUM LOADING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Potassium depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Potassium loading",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7264\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7264|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/33/11805\" title=\"figure 1\">",
"      Segmental potassium handling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/62/31725\" title=\"figure 2\">",
"      Loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/31/12797\" title=\"figure 3\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/43/39613\" title=\"figure 4\">",
"      Distal acid secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/32/35341\" title=\"figure 5\">",
"      PK and UK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/34/26157\" title=\"figure 6\">",
"      K and flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/35/32317\" title=\"figure 7\">",
"      Voltage effects on K handling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/18/17709\" title=\"figure 8\">",
"      Potassium adaptation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/26/18862\" title=\"figure 9\">",
"      Steady state response to K load",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=related_link\">",
"      Chapter 11A: Renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15766?source=related_link\">",
"      Chapter 13A: Meaning of urine electrolytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_24_11658="Electrocardiogram in the diagnosis of myocardial ischemia and infarction";
var content_f11_24_11658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/24/11658/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11658/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/24/11658/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11658/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11658/contributors\">",
"     David M Mirvis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/24/11658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/24/11658/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/24/11658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) is an important and central tool used to establish the diagnosis of myocardial ischemia or infarction. Abnormalities in the ST segment and T waves represent myocardial ischemia (and sometimes infarction) and may be followed by the formation of Q waves. However, the electrocardiogram may be normal or nonspecific in a patient with either ischemia or infarction. On the other hand, findings thought typical of acute myocardial infarction may occur in other conditions, such as myocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of the ECG for the diagnosis of myocardial ischemia and myocardial infarction (MI) will be reviewed here. This topic includes important updates on the ECG criteria for myocardial infarction (MI), including those made in the 2012 Joint European Society of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/World",
"    </span>",
"    Health Federation",
"    <span class=\"nowrap\">",
"     (ESC/ACCF/AHA/WHF)",
"    </span>",
"    Task Force in the Third Universal Definition of Myocardial Infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Also included in this report are specific ST segment (including elevation and depression) and T wave changes that may represent myocardial ischemia (",
"    <a class=\"graphic graphic_table graphicRef65591 \" href=\"UTD.htm?7/10/7339\">",
"     table 1",
"    </a>",
"    ), as well as changes in the QRS complex associated with prior myocardial infarction (",
"    <a class=\"graphic graphic_table graphicRef55068 \" href=\"UTD.htm?20/8/20619\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Localization of ischemia or infarction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The importance of the ECG in diagnosing ischemia and infarction was reinforced by the Myocardial Infarction Triage and Intervention (MITI) study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/2\">",
"     2",
"    </a>",
"    ]. The MITI project reviewed data on 3027 patients: ECG abnormalities were an early sign of myocardial ischemia and could be identified on a prehospital ECG within 90 minutes of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/2\">",
"     2",
"    </a>",
"    ]. Persistent and transient ST segment and T or Q wave abnormalities on serial ECGs discriminated patients with from those without acute ischemia or infarction better than changes on a single ECG; dynamic changes in ST segment elevation between serial ECGs improved the overall sensitivity from 34 to 46 percent. When serial evolution of all ECG abnormalities (ST segment, T or Q waves, or left bundle branch block) were considered, the diagnostic sensitivity of the ECG increased from 80 to 87 percent with a fall in specificity from 60 to 50 percent.",
"   </p>",
"   <p>",
"    It is also important to understand that ECG abnormalities are not the sole criteria for diagnosing MI. As will be described below, ECG changes may be absent or nonspecific, and when present may be due to ischemia without infarction or to non-ischemic disorders, such as acute pericarditis. Hence, infarction may be diagnosed by the appropriate combination of clinical and laboratory tests, in conjunction with (but not dependent upon) the presence of characteristic ECG changes.",
"   </p>",
"   <p>",
"    The findings on the ECG depend upon several characteristics of the ischemia or infarction including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration &mdash;",
"      <span class=\"nowrap\">",
"       hyperacute/acute",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       evolving/chronic",
"      </span>",
"     </li>",
"     <li>",
"      Size &mdash; amount of myocardium affected",
"     </li>",
"     <li>",
"      Localization &mdash; anterior versus inferior-posterior or right ventricle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the ECG may be affected by the presence of other underlying abnormalities and may provide information on prognosis.",
"   </p>",
"   <p>",
"    For example, the diagnosis is much more difficult to establish in patients with left bundle branch block or a paced rhythm and this topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=see_link\">",
"     \"Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of the ECG to estimate prognosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4521?source=see_link\">",
"     \"Electrocardiogram in the prognosis of myocardial infarction or unstable angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASIS OF INJURY CURRENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under normal conditions, the ST segment is relatively isoelectric (ie, flat along the baseline), because all healthy myocardial cells attain about the same potential during the plateau phase of repolarization, that is, during phase 2 of the cardiac action potential. Ischemia has complex time-dependent effects on the electrical properties of the affected myocardial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Severe, acute ischemia lowers the resting membrane potential (that is, makes it less negative), shortens the duration of the action potential, and changes the shape of the plateau (phase 2) of the action potential in the ischemic area. These changes create a voltage gradient between normal and ischemic zones, leading to current flow between these regions during both systolic (due to changes in the shape of the action potential) and diastolic (due to changes in the resting membrane potential) portions of the cardiac cycle. These so-called currents of injury are represented on the surface ECG by deviations of the ST segment from the isoelectric baseline. The polarity and magnitude of these changes depend upon the location and the severity of the insult.",
"   </p>",
"   <p>",
"    Although ST segment deviation in acute MI is often referred to as a \"current of injury,\" we will use the terms \"ischemia\" and \"infarction\" in this discussion and do not define \"injury\" as a separate category of ECG changes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When acute ischemia is transmural, the ST vector is usually shifted in the direction of the outer (epicardial) layers, producing ST elevations and sometimes tall positive (or hyperacute) T waves over the ischemic zone. The shift in the ST vector is due, at least in part, to ischemia-induced shortening of the action potential duration. This pathologic early repolarization causes the outside surface of ischemic cells to become positively charged relative to nonischemic cells which are still in a depolarized state (negative charge outside). The ECG vector always points away from negative and toward positive zones (in this case) toward the epicardium to produce ST segment elevation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A so-called \"diastolic current of injury\" due to lower myocardial membrane resting potential also contributes to the appearance of ST elevation on the ECG. The ECG vector created by this voltage gradient will be directed away from the epicardium to produce the equivalent of TP segment depression. Because the clinical ECG is \"capacitor coupled\" and the TP segment is used as the isoelectric baseline for measuring the other portions of the ECG waveform, this TP segment depression is not actually observed. Rather, lowering the baseline creates the appearance of greater ST-segment elevation. Thus, the observed ST elevation is due to both real ST elevation due to systolic currents of injury and the apparent elevation of the ST segment due to TP diastolic injury currents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When ischemia is confined primarily to the subendocardium, the systolic ST vector typically shifts toward the inner ventricular layer and the ventricular cavity and the diastolic injury vector points toward the epicardium, that is, the opposite of the directions with transmural ischemia. Thus, the overlying (eg, anterior precordial) leads show ST segment depression with ST elevation in lead aVR (reflecting the potentials present in the ventricular cavity) (",
"      <a class=\"graphic graphic_waveform graphicRef65963 \" href=\"UTD.htm?42/41/43674\">",
"       waveform 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple factors can affect the",
"    <strong>",
"     amplitude",
"    </strong>",
"    of acute ischemic ST deviations. Marked ST elevation or depression in multiple leads usually indicates severe ischemia or ischemia affecting large regions of the myocardium. Conversely, substantial (&ge;70 percent) resolution of ST elevation promptly following thrombolytic therapy is a robust predictor of both target vessel patency and outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. However, these relationships are not universal since severe ischemia or even MI can occur with slight or even absent ST-T changes.",
"   </p>",
"   <p>",
"    According to the 2012 Joint",
"    <span class=\"nowrap\">",
"     ESC/ACCF/AHA/WHF",
"    </span>",
"    Task Force, the following are the electrocardiographic manifestations of acute myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For ST elevation: New ST elevation at the J point in two contiguous leads with the cut-points: &ge;0.1 mV in all leads other than V2-V3 where the following cut-points apply: &ge;0.2 mV in men 40 years; &ge;0.25 mV in men &lt;40 years, or &ge;0.15 mV in women.",
"     </li>",
"     <li>",
"      For ST depression and T wave changes: New horizontal or down-sloping ST depression &ge;0.05 mV in two contiguous leads",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      T inversion &ge;0.1 mV in two contiguous leads with prominent R wave or",
"      <span class=\"nowrap\">",
"       R/S",
"      </span>",
"      ratio &gt;1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to emphasize that the ECG should always be evaluated in clinical context, with frequent serial tracings as indicated. All ECG criteria will result in both under- and over-diagnosis when applied too literally. This point is dramatized by the relatively high rate of false catheterization laboratory activations for presumed STEMI, reaching about 14 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ECG-coronary syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major types of acute coronary artery syndromes, in which myocardial ischemia leads to different ECG manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninfarction subendocardial ischemia (classic angina), manifested by transient ST segment depressions without QRS changes.",
"     </li>",
"     <li>",
"      Noninfarction transmural ischemia (eg, with Prinzmetal's variant angina and likely acute",
"      <span class=\"nowrap\">",
"       stress-induced/takotsubo",
"      </span>",
"      cardiomyopathy), manifested by transient ST segment elevations or paradoxical T wave normalization. Takotsubo syndrome may also cause an acute myocardial infarction in the absence of fixed coronary obstructions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"       \"Stress-induced (takotsubo) cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-ST elevation (non-Q wave) MI, manifested by ST depressions or T wave inversions without Q waves with corroborating laboratory evidence of infarction.",
"     </li>",
"     <li>",
"      ST elevation MI, manifested by ST elevations (or hyperacute T waves), and then by T wave inversions, often associated with evolution of pathologic Q waves.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LOCALIZATION OF ISCHEMIA OR INFARCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     ST segment elevation/Q waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG leads are more helpful in localizing regions of transmural than subendocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/9\">",
"     9",
"    </a>",
"    ]. In the acute setting, the anatomic location of the acute infarct is determined by which ECG leads show ST elevation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased T wave positivity (",
"    <a class=\"graphic graphic_table graphicRef65591 \" href=\"UTD.htm?7/10/7339\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Formation of Q waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of electromotive forces due to myocardial necrosis in a myocardial infarction leads to R wave loss. Delayed conduction through an ischemic area or conduction around it results in recording potentials from the opposite ventricular wall with Q wave formation in the appropriate leads.",
"   </p>",
"   <p>",
"    In the chronic postinfarction stage, localization of prior transmural events has been determined by the distribution of Q waves when present. Q waves usually follow a similar distribution to the acute ST and T wave abnormalities. In comparison, non-Q wave infarcts are generally considered subendocardial (ie, not transmural). Consistent with this hypothesis is the observation that the infarct-related artery is patent in 50 to 65 percent of cases when coronary arteriography is performed in the acute period following non-Q wave infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reason why Q waves do or do not develop following coronary occlusion is related to the duration of occlusion, the extent to which collateral vessels maintain myocardial viability during occlusion, and, ultimately, to the size of the infarct. Thus, the association between Q waves and transmural infarction is not simple.",
"   </p>",
"   <p>",
"    Q wave infarctions may be associated with non-transmural infarction and that non-Q wave infarction may be associated with transmural involvement. Therefore, it is best to describe infarcts electrocardiographically as Q wave or non-Q wave, rather than by the terms transmural or subendocardial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/3\">",
"     3",
"    </a>",
"    ]. Careful ECG-pathologic correlations have shown that transmural infarcts can occur without Q waves and that subendocardial infarcts can be associated with Q waves. In a study using cardiovascular magnetic resonance imaging, the presence or absence of Q waves was more closely correlated with the size of the MI than with its transmural extent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36868?source=see_link\">",
"     \"Pathogenesis and diagnosis of Q waves on the electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The findings may be somewhat different with posterior or lateral MI. Loss of depolarization forces in these regions can reciprocally",
"    <strong>",
"     increase",
"    </strong>",
"    R wave amplitude in leads V1 and V2, without causing diagnostic Q waves in any of the conventional leads. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Posterior wall MI'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Alternative methods for identifying prior infarctions, including fragmented QRS complexes, have been described, although there is much less experience with these findings than with Q waves. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Fragmented QRS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Criteria for abnormal Q waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the 2012 Joint",
"    <span class=\"nowrap\">",
"     ESC/ACCF/AHA/WHF",
"    </span>",
"    Task Force, the following are the criteria for ECG changes associated with prior myocardial infarction (in the absence of LVH or LBBB) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any Q wave in leads V2-V3 &ge;0.02 sec or QS complex in V2 and V3 or Q wave &ge;0.03 sec and &ge;0.01 mV deep or QS complex in leads I, II, aVL, aVF or V4-V6 in any two leads of a contiguous lead grouping (I, aVL; V1-V6; II, III, aVF).",
"     </li>",
"     <li>",
"      R wave &ge;0.04 s3ec in Va-V2 and",
"      <span class=\"nowrap\">",
"       R/S",
"      </span>",
"      &ge;1 with a concordant positive T wave in the absence of a conduction defect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Anatomic correlates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon autopsy studies and, more recently, various imaging modalities, the following classification system correlating the distribution of ST",
"    <span class=\"nowrap\">",
"     segment/T",
"    </span>",
"    wave abnormalities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Q waves with ischemia or infarct location has generally been accepted. Cardiac magnetic resonance imaging (CMR) also provides a means for comparing the anatomic distribution of an infarction with ECG findings. In a series of 51 patients, the pattern of Q waves matched the CMR findings in 80 to 100 percent of patients in each category [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Anterior and apical MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;ST elevation or Q waves in one or more of the precordial leads (V1-V6) and leads I and aVL has traditionally been used to suggest anterior wall ischemia or infarction (",
"    <a class=\"graphic graphic_waveform graphicRef81914 graphicRef62059 \" href=\"UTD.htm?0/5/84\">",
"     waveform 2A-B",
"    </a>",
"    ). Although characteristic ECG changes in leads V1 to V3 are considered typical of anteroseptal ischemia, they may be more indicative of apical ischemia. This was illustrated in a review of 50 patients with new Q waves in leads V1 to V3 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/17\">",
"     17",
"    </a>",
"    ]. Echocardiography and angiography showed that the apex was affected in all patients and was the only involved site in 26; the septum and anterior and lateral walls were also affected in the remaining 24 patients, but the degree of involvement was less severe than in the apex.",
"   </p>",
"   <p>",
"    Similar findings were noted in another analysis in which 48 of 52 patients with acute ST segment elevations in leads V1 to V3 had an antero-apical infarct and a normal septum [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/18\">",
"     18",
"    </a>",
"    ]. Changes in leads V4 to V6 suggest anterolateral ischemia or infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Inferior and right ventricular MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;ST segment shifts or Q waves in leads II, III, and aVF suggest inferior wall ischemia or infarction (",
"    <a class=\"graphic graphic_waveform graphicRef82739 \" href=\"UTD.htm?42/21/43354\">",
"     waveform 3",
"    </a>",
"    ). If there is evidence of inferior wall ischemia, right-sided leads, especially V3R and V4Rshould also be obtained to assess for a possible right ventricular",
"    <span class=\"nowrap\">",
"     ischemia/infarction",
"    </span>",
"    (",
"    <a class=\"graphic graphic_waveform graphicRef82739 \" href=\"UTD.htm?42/21/43354\">",
"     waveform 3",
"    </a>",
"    ). Recording of right-sided leads is, therefore, recommended in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Posterior wall MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute posterior wall MI induces ST elevations in leads placed over the back of the heart, eg, esophageal leads or leads V7 to V9 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Concomitant ST elevations are often present in the inferior leads (II, III, aVF), reflecting inferior wall involvement (",
"    <a class=\"graphic graphic_waveform graphicRef70036 \" href=\"UTD.htm?41/28/42442\">",
"     waveform 4",
"    </a>",
"    ). Reciprocal ST depressions may be present in the anterior leads (eg, V1-V3).",
"   </p>",
"   <p>",
"    The ST elevations of acute posterior MI are usually associated with reciprocal ST depressions in leads V1 to V3. Similar ST changes can also be the primary ECG manifestation of anterior subendocardial ischemia that may occur in combination with inferior infarction. Posterior inferior wall MI can be differentiated from anterior wall ischemia by the presence of ST segment elevations in the inferior (II, III, aVF) and posterior leads V7 to V9 (",
"    <a class=\"graphic graphic_table graphicRef72039 \" href=\"UTD.htm?11/27/11707\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/19,20,22\">",
"     19,20,22",
"    </a>",
"    ]. Relatively tall R waves may also appear in leads V1-V3 (",
"    <a class=\"graphic graphic_waveform graphicRef70036 \" href=\"UTD.htm?41/28/42442\">",
"     waveform 4",
"    </a>",
"    ), corresponding to the appearance of pathologic Q waves (loss of depolarization forces) in the posterior leads.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Multiple regions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, ischemia affects more than one region of the myocardium. In this setting, the ECG should show the characteristic findings of involvement in each region (",
"    <a class=\"graphic graphic_waveform graphicRef54339 \" href=\"UTD.htm?41/42/42666\">",
"     waveform 5",
"    </a>",
"    ). However, partial normalization may result from cancellation of opposing vectorial forces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Extent of the infarct",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of abnormalities can also provide information about the extent of the infarct. As an example, the presence of significant ST segment elevation (&gt;2 mm) in leads V5 to V6 in association with an inferior wall MI is a sensitive and specific (94 and 98 percent, respectively) sign of a very large infarct-related artery and a large area of involved myocardium (inferior and lateral walls) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4521?source=see_link&amp;anchor=H6#H6\">",
"     \"Electrocardiogram in the prognosis of myocardial infarction or unstable angina\", section on 'Extent of myocardial injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Identification of the infarct-related artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG may also provide information about the location of the occlusion within the coronary system in patients with an ST elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Inferior MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with an inferior wall MI have occlusion of either the right coronary artery or the left circumflex coronary artery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of ST segment elevation in lead III exceeding that in lead II, particularly when combined with ST depression in leads I and aVL, is reported as a very useful predictor of an occlusion in the proximal or mid portion of the right coronary artery, with high sensitivity and specificity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. However, more recent data in a larger cohort suggests that the sensitivity of this sign may only be 70 percent, with specificity of about 72 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of ST segment elevation in lead II, which is equal to that of lead III, especially when combined with ST depression in leads V1 to V3 or ST elevation in leads I and aVL, is a useful but not absolute predictor of a left circumflex coronary artery occlusion; these findings may also be seen in distal occlusion of a dominant right coronary artery [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/24,26\">",
"       24,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a series of 109 patients presenting with an inferior wall MI who underwent angiography, the presence of concomitant precordial ST segment depression was a sensitive, but not specific, indicator of left circumflex occlusion; however, the absence of precordial ST segment depression had a high negative predictive value for excluding the left circumflex artery as the culprit vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients with an inferior MI have right-sided ST elevation in leads V1 and V4R; this finding is indicative of acute right ventricular injury [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/24,27-29\">",
"       24,27-29",
"      </a>",
"      ] and correlates closely with occlusion of the",
"      <strong>",
"       proximal right coronary artery",
"      </strong>",
"      . In one report, ST elevation in V4R had 88 percent sensitivity and 78 percent specificity for concurrent right ventricular infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Anterior MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with an anterior wall MI have occlusion of the left anterior descending coronary artery. The presence of ST elevation in lead aVR, complete right bundle branch block, ST depression in lead V5,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ST elevation in V1 greater than 2.5 mm strongly predicts a left anterior descending (LAD) artery occlusion proximal to the first septal perforator [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following additional observations with acute MI due to LAD occlusion have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal Q waves in only V4 to V6 are associated with an occlusion distal to the first septal perforator [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An abnormal Q wave in aVL is associated with an LAD occlusion proximal to the first diagonal branch, while ST depression in aVL suggests an occlusion distal to the first diagonal [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inferior ST depression &ge;1 mm plus ST elevation in aVL predicts an LAD occlusion proximal to both the septal perforator and diagonal while the absence of inferior ST depression is associated with a distal occlusion [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Deep \"coronary\" T wave inversions in multiple precordial leads (eg, V1-V4) are typically caused by a tight stenosis in the LAD [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/32-35\">",
"       32-35",
"      </a>",
"      ]. These patients often present without Q waves. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Other ischemic ST-T patterns'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Simultaneous ST elevations in both the anterior and inferior leads raises consideration of occlusion of an LAD that is unusually long, wrapping around the apex to supply the distal inferior wall. This variant has been referred to as a \"wrap around\" LAD [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/36\">",
"       36",
"      </a>",
"      ]. However, ST elevation in leads II, III and aVF may also occur with more distal occlusion of the LAD, that is after the first diagonal branch such that the injury current vector points in a more inferior direction [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ST elevation in lead aVR that is greater than or equal to ST elevation in lead V1 may be useful for diagnosing an acute left main coronary artery obstruction. In a report in which 16 such patients were compared to 46 with LAD obstruction and 24 with right coronary artery obstruction, the above finding distinguished left main coronary occlusion from an LAD occlusion with a sensitivity and specificity of 81 and 80 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, mortality was associated with a greater degree of ST elevation in aVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Evolution in infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A series of characteristic ECG changes are often seen as an MI evolves. In the very early stages, the initial ECG may be normal. Relatively tall, broad-based hyperacute T waves may precede ST segment shifts. When ischemic ST elevations occur as the earliest sign of acute MI, they are typically followed within a period ranging from hours to days by evolving T wave inversions, and sometimes Q waves, in the same lead distribution (",
"    <a class=\"graphic graphic_waveform graphicRef81914 graphicRef62059 \" href=\"UTD.htm?0/5/84\">",
"     waveform 2A-B",
"    </a>",
"    ). T wave inversions due to evolving or chronic ischemia correlate with increased action potential duration and are often associated with Q-T prolongation.",
"   </p>",
"   <p>",
"    The T wave inversions may resolve after days or weeks or persist indefinitely. The extent of the infarct may be an important determinant of T wave evolution. In one series, T waves that were persistently negative for more than one year in leads with Q waves were associated with a transmural MI with fibrosis of the entire wall; in contrast, T waves that were positive in leads with Q waves were indicative of a nontransmural MI with viable myocardium within the wall [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/38\">",
"     38",
"    </a>",
"    ]. The resolution of negative T waves also predicts recovery of regional left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complete normalization of the ECG following Q wave MI is uncommon but can occur, particularly with smaller infarcts and when left ventricular ejection fraction and regional wall motion improve. The latter changes are usually associated with spontaneous recanalization or good collateral circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/40\">",
"     40",
"    </a>",
"    ]. In contrast, persistent Q waves and ST elevations several weeks or more after an infarct correlate strongly with a severe underlying wall motion disorder (akinetic or dyskinetic zone), although not necessarily a frank ventricular aneurysm (",
"    <a class=\"graphic graphic_waveform graphicRef74283 \" href=\"UTD.htm?40/14/41194\">",
"     waveform 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other ischemic ST-T patterns",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Non-ST elevation (non-Q wave)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with non-Q wave infarctions typically present with ST segment depression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T wave inversion in two or more leads. As noted above, reciprocal ST segment depression can occur during an ST elevation MI. For this reason, ST segment elevation, which is sometimes subtle, should be sought in opposing leads whenever ST segment depression is noted (eg, if ST depression is seen in leads V1 through V3, leads II, III, and aVF, and the",
"    <span class=\"nowrap\">",
"     lateral/posterior",
"    </span>",
"    chest leads should be evaluated for concomitant ST elevation).",
"   </p>",
"   <p>",
"    As noted above, the association between Q waves and transmural infarction has been questioned and the presence or absence of Q waves may be more closely correlated with the size of the MI than with its transmural extent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Formation of Q waves'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36868?source=see_link\">",
"     \"Pathogenesis and diagnosis of Q waves on the electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Coronary vasospasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversible transmural ischemia, due for example to epicardial coronary vasospasm, may cause transient ST segment elevations. This syndrome is called Prinzmetal's variant angina. Depending upon the severity and duration of such non-infarction ischemia, the ST elevations may either resolve completely within minutes or be followed by T wave inversions that persist for hours or even days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link\">",
"     \"Variant angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Stress-induced cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress-induced (&ldquo;takotsubo&rdquo;) cardiomyopathy, sometimes called transient left ventricular ballooning syndrome, is marked by reversible wall motion abnormalities of the left ventricular apex and mid-ventricle. The typical patient is a post-menopausal woman who presents with chest pain, ST elevations, and elevated cardiac enzyme levels mimicking a classic myocardial infarction. The syndrome is characteristically reported in the context of severe emotional or physiologic stress. Fixed epicardial disease is not present. The underlying pathophysiology is not certain but may relate to diffuse coronary vasospasm or neurogenically mediated myocardial damage [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     LAD-T wave inversion pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with ischemic chest pain present with deep \"coronary\" T wave inversions in multiple precordial leads (eg, V1-V4) with or without cardiac enzyme elevations and with minimal or no ST elevations. This pattern, sometimes called the Wellens' syndrome or the LAD-T wave inversion pattern, is typically caused by a tight stenosis in the left anterior descending coronary artery system (",
"    <a class=\"graphic graphic_waveform graphicRef67865 \" href=\"UTD.htm?42/42/43683\">",
"     waveform 7",
"    </a>",
"    ). The natural history of this pattern is unfavorable, with a high incidence of recurrent symptoms and MI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Prominent symmetrical T-wave inversions in the anterior precordial leads may also indicate a regional wall motion abnormality that may be reversible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Pseudonormalization of T waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose baseline ECG already shows abnormal T wave inversions may develop paradoxical T wave normalization (pseudonormalization) during episodes of acute transmural ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     LIMITATIONS IN THE DIAGNOSIS OF ISCHEMIA AND INFARCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG has important limitations in both sensitivity and specificity for the diagnosis of acute coronary syndromes and chronic infarction. With regard to acute ischemia, these issues have become more important with the widespread use of rapid thrombolytic therapy or revascularization procedures. Underdiagnosis would lead to undertreatment, while overdiagnosis would expose patients to unwarranted risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Potential underdiagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initially normal ECG does not exclude ischemia or even acute infarction. However, a normal ECG throughout the course of acute MI is distinctly uncommon. Thus, if the initial ECG is not diagnostic, but the patient remains symptomatic and there is a high clinical suspicion for MI, it is recommended that the ECG be repeated at 5 to 10 minute intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolonged chest pain without diagnostic ECG changes should always prompt a careful search for noncoronary causes of chest pain. Some of these disorders are also potentially life-threatening (eg, aortic dissection, pulmonary embolism, esophageal rupture). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pathologic Q waves may also be absent in patients with coronary artery disease and left ventricular dysfunction. In one study, for example, the presence of any pathologic Q wave had a sensitivity of 57 percent and specificity of 80 percent, for identifying severe coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of mechanisms that could explain the absence of Q waves in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-Q wave MI. In a cardiovascular magnetic resonance imaging study cited above, the presence or absence of Q waves was more closely correlated with the size of the MI than with its transmural extent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Formation of Q waves'",
"      </a>",
"      above.) Thus, small infarcts may not cause abnormal Q waves to appear.",
"     </li>",
"     <li>",
"      Infarction in areas that are electrically \"silent,\" that is, in areas that project potentials to regions on the body surface on which there are no electrodes.",
"     </li>",
"     <li>",
"      Chronically ischemic or \"hibernating\" but noninfarcted myocardium. The ECG Q wave burden is associated with the presence of scars but does not accurately predict the amount of hibernating myocardium [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=see_link\">",
"       \"Clinical syndromes of stunned or hibernating myocardium\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Resolution of the Q wave. Approximately 10 percent of anterior and 25 percent of inferior MIs revert to a nondiagnostic pattern within two years after the infarct, and a higher percentage have a diminution in Q wave area [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/48-50\">",
"       48-50",
"      </a>",
"      ]. Functional recovery of stunned myocardium contributes to Q wave resolution [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other concomitant conduction disorders such as left bundle branch block, electronic ventricular pacemaker patterns, and Wolff-Parkinson-White syndrome that obscure the emergence of new Q waves.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Fragmented QRS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because Q waves are not always present and may regress over time, alternative ECG markers of prior infarction have been evaluated, including a fragmented QRS complex. Because regions of myocardial scar produce slow and disorganized conduction, the QRS morphology in the leads overlying scar may be altered and prolonged.",
"   </p>",
"   <p>",
"    The diagnostic performance of QRS fragmentation was evaluated in a series of 479 patients referred for stress testing with nuclear imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/51\">",
"     51",
"    </a>",
"    ]. QRS fragmentation was said to be present if any of a number of abnormal QRS morphologies, including an R' and notching of the S wave, were present in two or more anatomically contiguous leads. Prior myocardial infarction was diagnosed on the basis of fixed perfusion defects on nuclear images. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QRS fragmentation was more common than Q waves (42 versus 15 percent).",
"     </li>",
"     <li>",
"      A fragmented QRS was more sensitive for a prior infarction than Q waves (86 versus 36 percent), but less specific (99 versus 89 percent).",
"     </li>",
"     <li>",
"      The absence of QRS fragmentation had a high negative predictive value for prior infarction (93 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further investigation will be necessary both to confirm these results, and to develop consistent definitions for QRS fragmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Left bundle branch block",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of left bundle branch block often obscures the classical electrocardiographic diagnosis of acute MI. Assessment of ST segment changes may be useful in this setting. ST segment shifts that occur in the same direction as the major QRS vector (so-called \"primary\" or concordant ST changes) can indicate ischemia or infarction. Such shifts may include ST depression of at least 1 mm in leads V1, V2, or V3 or in leads II, III or aVF, with elevation of at least 1 mm in lead V5. Extremely discordant ST changes (changes in the opposite direction of the major QRS vector of &gt;5 mm) were also reported to be suggestive of MI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/24,53\">",
"     24,53",
"    </a>",
"    ], although exceptions occur, importantly limiting the specificity of this sign. This issue is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=see_link\">",
"     \"Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Potential overdiagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians may overdiagnose ischemia or infarction based upon the presence of ST elevations or depressions, T wave inversions, tall positive T waves, tall positive R waves in",
"    <span class=\"nowrap\">",
"     V1/V2",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef72039 \" href=\"UTD.htm?11/27/11707\">",
"     table 3",
"    </a>",
"    ), or Q waves not related to coronary disease (pseudo-infarct patterns).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ST elevations can occur in numerous other conditions (",
"      <a class=\"graphic graphic_table graphicRef81757 \" href=\"UTD.htm?38/35/39483\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/54\">",
"       54",
"      </a>",
"      ]. The disorders most commonly mistaken for an acute MI include acute pericarditis and acute myocarditis, and as a normal variant (\"early repolarization\") pattern. The Brugada pattern, with ST elevations",
"      <span class=\"nowrap\">",
"       V-V2/V3,",
"      </span>",
"      is another cause of nonischemic ST-segment elevations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ST elevations also occur in the early phase of acute stress-induced (takotsubo) cardiomyopathy, sometimes called \"transient left ventricular ballooning syndrome,\" which is marked by reversible left ventricular (apex and mid-ventricle) wall motion abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"       \"Stress-induced (takotsubo) cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are a variety of causes of Q waves other than MI (",
"      <a class=\"graphic graphic_table graphicRef58569 \" href=\"UTD.htm?35/15/36091\">",
"       table 5",
"      </a>",
"      ). As an example, Q waves are not uncommonly seen in patients with nonischemic cardiomyopathy with depressed left ventricular function [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/45\">",
"       45",
"      </a>",
"      ]. A probable explanation is that such patients are more likely to have left ventricular conduction delays. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36868?source=see_link\">",
"       \"Pathogenesis and diagnosis of Q waves on the electrocardiogram\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overdiagnosis may result in unwarranted and potentially hazardous treatments, long-lasting mislabeling of patients as having ischemic heart disease, and prevention of the detection and treatment of the true cause of the patient's clinical presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Distinction from acute pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pericarditis, in contrast to acute MI, typically induces diffuse ST segment elevations, usually in most of the chest leads and also in leads I, aVL, II, and aVF. Reciprocal ST depression is seen in lead aVR. An important clue to pericarditis in addition to the diffuse nature of the ST elevations is the presence of PR segment elevation in aVR with PR segment depressions in other leads due to a concomitant atrial current of injury (",
"    <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"UTD.htm?42/53/43866\">",
"     waveform 8",
"    </a>",
"    ). Abnormal Q waves do not occur and the ST elevation is followed by T wave inversion after a variable time period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=see_link\">",
"     \"Electrocardiogram in pericarditis and pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Distinction from acute myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocarditis can, in some patients, simulate the ECG pattern of acute pericarditis or acute MI. Like acute MI, myocarditis may be associated with regional ST elevations and Q waves, elevated serum concentrations of CK-MB, and regional wall motion abnormalities on echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Myocarditis should be suspected in young patients who present with a possible MI but have a normal coronary angiogram. In one study of 45 such patients, 35 (78 percent) had a diffuse or focal myocarditis on myocardial imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/56\">",
"     56",
"    </a>",
"    ]. Complete recovery of left ventricular function occurred at six months in 81 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Distinction from early repolarization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some healthy subjects, particularly young men, the ECG shows normal variant ST segment elevations (2-3 mm) that are usually best seen in the mid- chest leads, that is V3-V4 (",
"    <a class=\"graphic graphic_waveform graphicRef79999 \" href=\"UTD.htm?27/15/27892\">",
"     waveform 9",
"    </a>",
"    ). Reciprocal ST depressions may be present, but limited to lead aVR. ST elevations may be seen in the limb leads, but are less than 1mm. This pattern has been referred to as early repolarization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/38/38505?source=see_link\">",
"     \"Early repolarization\"",
"    </a>",
"    .) The pattern is stable over time, but may be less marked at faster heart rates and more apparent at slower ones, associated with vagal tone changes.",
"   </p>",
"   <p>",
"    The ability to rapidly differentiate early repolarization from anterior ST-elevation myocardial infarction (STEMI) is important in the evaluation of patients with ischemic chest pain. In a retrospective study of the electrocardiograms of 143 patients with STEMI who had ECGs in which the changes in the anterior lead were not obvious for MI and 171 patients with early repolarization, three measurements were found to be useful for discrimination [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/57\">",
"     57",
"    </a>",
"    ]. The combination of greater ST-segment elevation (60 ms after the J point in lead V3), lower R-wave amplitude (in lead V4), and longer corrected QT interval was predictive (88 percent accuracy) of STEMI. These criteria need to be validated in a larger study before we recommend their use.",
"   </p>",
"   <p>",
"    Ongoing efforts to&nbsp;extract robust&nbsp;ECG differential diagnostic findings between early repolarization and acute MI are underway; prospectively tested criteria applicable to individual patients&nbsp;remain to be developed.&nbsp;The challenges of defining criteria to separate these two entities are compounded because the two patterns may co-exist (eg, early repolarization in a young person with acute ischemia or early repolarization with a non-thrombotic cause of ST-segment elevation, such as coronary vasospasm). In all situations, comparison with prior ECGs may be particularly useful.",
"   </p>",
"   <p>",
"    A small subset of individuals with an ECG consistent with early repolarization have received attention because of apparently increased vulnerability to ventricular tachyarrhythmias and sudden cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/58\">",
"     58",
"    </a>",
"    ]. In one large community-based study of middle-aged subjects from Finland, ST elevation of 1mm or more in the inferior limb leads was identified as a potential marker of arrhythmic risk [",
"    <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/59\">",
"     59",
"    </a>",
"    ]. Further delineation of \"benign\" versus potentially \"malignant\" varieties of early repolarization is needed to address this important issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the varying causes of ST elevation, tall positive T waves do not invariably represent hyperacute ischemic changes but can reflect normal variants, hyperkalemia, cerebrovascular injury, left ventricular volume loads due to mitral or aortic regurgitation, among other causes. ST elevations and tall positive T waves are also common findings in leads V1 and V2 with left bundle branch block or left ventricular hypertrophy patterns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22689?source=see_link\">",
"     \"Differential diagnosis of basic electrocardiographic abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Q waves, ST depression, and T wave inversion can also be caused by disorders other than infarction or ischemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of Q waves includes physiologic or positional variants, ventricular hypertrophy, acute or chronic noncoronary myocardial injury, Wolff-Parkinson-White preexcitation pattern, and ventricular conduction disorders, especially left bundle branch block (",
"      <a class=\"graphic graphic_table graphicRef58569 \" href=\"UTD.htm?35/15/36091\">",
"       table 5",
"      </a>",
"      ). The definition of abnormal Q waves has evolved. Classical teachings indicate that a Q wave must be 40 msec wide or wider to be considered abnormal. Newer studies, however, suggest that Q waves with durations of over 30 msec in leads I, II, aVL, aVF, or V4 to V6 may be equally diagnostic [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Criteria for abnormal Q waves'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36868?source=see_link\">",
"       \"Pathogenesis and diagnosis of Q waves on the electrocardiogram\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Digitalis, ventricular hypertrophy, hypokalemia and a variety of other factors can cause ST depression mimicking subendocardial ischemia.",
"     </li>",
"     <li>",
"      Prominent T wave inversions can occur in a number of conditions including ventricular hypertrophy, cardiomyopathy, myocarditis, cerebrovascular injury, particularly intracranial hemorrhage (",
"      <a class=\"graphic graphic_waveform graphicRef56660 \" href=\"UTD.htm?29/34/30255\">",
"       waveform 10",
"      </a>",
"      ), intermittent ventricular pacing (post-pacemaker T wave changes), and with intermittent left bundle branch block ventricular pacing or ventricular pre-excitation (\"memory T waves\") [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/35,61\">",
"       35,61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       \"Patient information: ECG and stress test (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22491416\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) is an important and often central tool used to establish the diagnosis of myocardial ischemia or infarction. New abnormalities in the ST segment and T waves may represent myocardial ischemia (and sometimes infarction) and may be followed by the formation of Q waves. However, the electrocardiogram may be normal or nonspecific in a patient with either ischemia or infarction. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following represent some of important points covered in this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Q waves, assuming correct lead placement, are usually abnormal (although not necessarily due to myocardial infarction) in the following contexts: present in leads V2-V3 and &ge;20 msec, a QS complex in leads V2- V3, or any Q wave &ge;30 msec and &ge;0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6. These changes must be present in any two leads of a contiguous lead grouping. An isolated QS or Qr wave in lead V1 may be normal. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Criteria for abnormal Q waves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ST elevation or Q waves in one or more of the precordial leads (V1-V6) and leads I and aVL has traditionally been used to suggest anterior wall ischemia or infarction. Patients presenting with an anterior wall MI often have occlusion of the left anterior descending coronary artery. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Anterior and apical MI'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Anterior MI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ST segment shifts or Q waves in leads II, III, and aVF suggest inferior wall ischemia or infarction. Patients presenting with an inferior wall MI usually have occlusion of either the right coronary artery or the left circumflex coronary artery. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inferior and right ventricular MI'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Inferior MI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ECG diagnosis of acute posterior wall MI is associated with ST elevations in leads placed over the back of the heart, eg, esophageal leads or leads V7 to V9, often with reciprocal ST depressions in leads V1 and V2. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Posterior wall MI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A series of characteristic ECG changes are often seen as an MI evolves. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Evolution in infarction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with non-Q wave infarctions typically present with ST segment depression",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      T wave inversion in two or more leads. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Non-ST elevation (non-Q wave)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ECG has important limitations in both sensitivity and specificity for the diagnosis of acute coronary syndromes and chronic infarction. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Limitations in the diagnosis of ischemia and infarction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ST elevations can occur in numerous other conditions (",
"      <a class=\"graphic graphic_table graphicRef81757 \" href=\"UTD.htm?38/35/39483\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/24/11658/abstract/54\">",
"       54",
"      </a>",
"      ]. The non-coronary disorders most commonly mistaken for an acute ST elevation MI include acute",
"      <span class=\"nowrap\">",
"       Pericarditis/acute",
"      </span>",
"      myocarditis, and normal variants (including the \"early repolarization\" pattern). The Brugada pattern, with ST elevations",
"      <span class=\"nowrap\">",
"       V-V2/V3,",
"      </span>",
"      is another cause of nonischemic ST-segment elevations. ST elevations due to acute ischemia without actual thrombotic obstructive coronary occlusion include Prinzmetal&rsquo;s (vasospastic) angina and the takotsubo (&ldquo;stress cardiomyopathy&rdquo;) syndrome. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Potential overdiagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/1\">",
"      Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/2\">",
"      Kudenchuk PJ, Maynard C, Cobb LA, et al. Utility of the prehospital electrocardiogram in diagnosing acute coronary syndromes: the Myocardial Infarction Triage and Intervention (MITI) Project. J Am Coll Cardiol 1998; 32:17.",
"     </a>",
"    </li>",
"    <li>",
"     Mirvis DM, Goldberger AL. Electrocardiography. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 9th edition, Bonow RO, Mann DL, Zipes DP, Libby P (Eds), W.B. Saunders Company, Philadelphia 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/4\">",
"      Wagner GS, Macfarlane P, Wellens H, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009; 53:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/5\">",
"      Zeymer U, Schr&ouml;der R, Tebbe U, et al. Non-invasive detection of early infarct vessel patency by resolution of ST-segment elevation in patients with thrombolysis for acute myocardial infarction; results of the angiographic substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 trial. Eur Heart J 2001; 22:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/6\">",
"      Schr&ouml;der K, Wegscheider K, Zeymer U, et al. Extent of ST-segment deviation in a single electrocardiogram lead 90 min after thrombolysis as a predictor of medium-term mortality in acute myocardial infarction. Lancet 2001; 358:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/7\">",
"      Zeymer U, Schr&ouml;der K, Wegscheider K, et al. ST resolution in a single electrocardiographic lead: a simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarction. Am Heart J 2005; 149:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/8\">",
"      Larson DM, Menssen KM, Sharkey SW, et al. \"False-positive\" cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction. JAMA 2007; 298:2754.",
"     </a>",
"    </li>",
"    <li>",
"     Goldberger, AL. Clinical Electrocardiography: A Simplified Approach, 7th ed, Mosby, Inc, St. Louis 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/10\">",
"      Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/11\">",
"      Liebson PR, Klein LW. The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/12\">",
"      Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993; 87:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/13\">",
"      Kerensky RA, Wade M, Deedwania P, et al. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol 2002; 39:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/14\">",
"      Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002; 106:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/15\">",
"      Moon JC, De Arenaza DP, Elkington AG, et al. The pathologic basis of Q-wave and non-Q-wave myocardial infarction: a cardiovascular magnetic resonance study. J Am Coll Cardiol 2004; 44:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/16\">",
"      Bay&eacute;s de Luna A, Cino JM, Pujadas S, et al. Concordance of electrocardiographic patterns and healed myocardial infarction location detected by cardiovascular magnetic resonance. Am J Cardiol 2006; 97:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/17\">",
"      Bogaty P, Boyer L, Rousseau L, Arsenault M. Is anteroseptal myocardial infarction an appropriate term? Am J Med 2002; 113:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/18\">",
"      Shalev Y, Fogelman R, Oettinger M, Caspi A. Does the electrocardiographic pattern of \"anteroseptal\" myocardial infarction correlate with the anatomic location of myocardial injury? Am J Cardiol 1995; 75:763.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/20\">",
"      Casas RE, Marriott HJ, Glancy DL. Value of leads V7-V9 in diagnosing posterior wall acute myocardial infarction and other causes of tall R waves in V1-V2. Am J Cardiol 1997; 80:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/21\">",
"      Kulkarni AU, Brown R, Ayoubi M, Banka VS. Clinical use of posterior electrocardiographic leads: a prospective electrocardiographic analysis during coronary occlusion. Am Heart J 1996; 131:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/22\">",
"      Kontos MC, Desai PV, Jesse RL, Ornato JP. Usefulness of the admission electrocardiogram for identifying the infarct-related artery in inferior wall acute myocardial infarction. Am J Cardiol 1997; 79:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/23\">",
"      Assali AR, Sclarovsky S, Herz I, et al. Comparison of patients with inferior wall acute myocardial infarction with versus without ST-segment elevation in leads V5 and V6. Am J Cardiol 1998; 81:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/24\">",
"      Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 2003; 348:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/25\">",
"      Zimetbaum PJ, Krishnan S, Gold A, et al. Usefulness of ST-segment elevation in lead III exceeding that of lead II for identifying the location of the totally occluded coronary artery in inferior wall myocardial infarction. Am J Cardiol 1998; 81:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/26\">",
"      Verouden NJ, Barwari K, Koch KT, et al. Distinguishing the right coronary artery from the left circumflex coronary artery as the infarct-related artery in patients undergoing primary percutaneous coronary intervention for acute inferior myocardial infarction. Europace 2009; 11:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/27\">",
"      Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994; 330:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/28\">",
"      Zehender M, Kasper W, Kauder E, et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 1993; 328:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/29\">",
"      Herz I, Assali AR, Adler Y, et al. New electrocardiographic criteria for predicting either the right or left circumflex artery as the culprit coronary artery in inferior wall acute myocardial infarction. Am J Cardiol 1997; 80:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/30\">",
"      Engelen DJ, Gorgels AP, Cheriex EC, et al. Value of the electrocardiogram in localizing the occlusion site in the left anterior descending coronary artery in acute anterior myocardial infarction. J Am Coll Cardiol 1999; 34:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/31\">",
"      Arbane M, Goy JJ. Prediction of the site of total occlusion in the left anterior descending coronary artery using admission electrocardiogram in anterior wall acute myocardial infarction. Am J Cardiol 2000; 85:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/32\">",
"      Haines DE, Raabe DS, Gundel WD, Wackers FJ. Anatomic and prognostic significance of new T-wave inversion in unstable angina. Am J Cardiol 1983; 52:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/33\">",
"      de Zwaan C, B&auml;r FW, Janssen JH, et al. Angiographic and clinical characteristics of patients with unstable angina showing an ECG pattern indicating critical narrowing of the proximal LAD coronary artery. Am Heart J 1989; 117:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/34\">",
"      Rhinehardt J, Brady WJ, Perron AD, Mattu A. Electrocardiographic manifestations of Wellens' syndrome. Am J Emerg Med 2002; 20:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/35\">",
"      Shvilkin A, Ho KK, Rosen MR, Josephson ME. T-vector direction differentiates postpacing from ischemic T-wave inversion in precordial leads. Circulation 2005; 111:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/36\">",
"      Sasaki K, Yotsukura M, Sakata K, et al. Relation of ST-segment changes in inferior leads during anterior wall acute myocardial infarction to length and occlusion site of the left anterior descending coronary artery. Am J Cardiol 2001; 87:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/37\">",
"      Yamaji H, Iwasaki K, Kusachi S, et al. Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography. ST segment elevation in lead aVR with less ST segment elevation in lead V(1). J Am Coll Cardiol 2001; 38:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/38\">",
"      Maeda S, Imai T, Kuboki K, et al. Pathologic implications of restored positive T waves and persistent negative T waves after Q wave myocardial infarction. J Am Coll Cardiol 1996; 28:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/39\">",
"      Bosimini E, Giannuzzi P, Temporelli PL, et al. Electrocardiographic evolutionary changes and left ventricular remodeling after acute myocardial infarction: results of the GISSI-3 Echo substudy. J Am Coll Cardiol 2000; 35:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/40\">",
"      Nagase K, Tamura A, Mikuriya Y, Nasu M. Significance of Q-wave regression after anterior wall acute myocardial infarction. Eur Heart J 1998; 19:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/41\">",
"      Akashi YJ, Nef HM, M&ouml;llmann H, Ueyama T. Stress cardiomyopathy. Annu Rev Med 2010; 61:271.",
"     </a>",
"    </li>",
"    <li>",
"     file://jama.ama-assn.org/content/306/3/277.short (Accessed on December 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/43\">",
"      Parodi O, Uthurralt N, Severi S, et al. Transient reduction of regional myocardial perfusion during angina at rest with ST-segment depression or normalization of negative T waves. Circulation 1981; 63:1238.",
"     </a>",
"    </li>",
"    <li>",
"     Antman, EM, Anbe, DT, Armstrong, PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on June 07, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/45\">",
"      Pirwitz MJ, Lange RA, Landau C, et al. Utility of the 12-lead electrocardiogram in identifying underlying coronary artery disease in patients with depressed left ventricular systolic function. Am J Cardiol 1996; 77:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/46\">",
"      Ananthasubramaniam K, Chow BJ, Ruddy TD, et al. Does electrocardiographic Q wave burden predict the extent of scarring or hibernating myocardium as quantified by positron emission tomography? Can J Cardiol 2005; 21:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/47\">",
"      Al-Mohammad A, Norton MY, Mahy IR, et al. Can the surface electrocardiogram be used to predict myocardial viability? Heart 1999; 82:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/48\">",
"      Davidoff R, Goldman AP, Diamond TH, et al. The natural history of the Q wave in inferoposterior myocardial infarction. S Afr Med J 1982; 61:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/49\">",
"      Richter A, Herlitz J, Hjalmarson A. QRS complex recovery during one year after acute myocardial infarction. Clin Cardiol 1987; 10:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/50\">",
"      Voon WC, Chen YW, Hsu CC, et al. Q-wave regression after acute myocardial infarction assessed by Tl-201 myocardial perfusion SPECT. J Nucl Cardiol 2004; 11:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/51\">",
"      Das MK, Khan B, Jacob S, et al. Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease. Circulation 2006; 113:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/52\">",
"      Das MK, Zipes DP. Fragmented QRS: a predictor of mortality and sudden cardiac death. Heart Rhythm 2009; 6:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/53\">",
"      Sgarbossa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. N Engl J Med 1996; 334:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/54\">",
"      Wang K, Asinger RW, Marriott HJ. ST-segment elevation in conditions other than acute myocardial infarction. N Engl J Med 2003; 349:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/55\">",
"      Angelini A, Calzolari V, Calabrese F, et al. Myocarditis mimicking acute myocardial infarction: role of endomyocardial biopsy in the differential diagnosis. Heart 2000; 84:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/56\">",
"      Sarda L, Colin P, Boccara F, et al. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. J Am Coll Cardiol 2001; 37:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/57\">",
"      Smith SW, Khalil A, Henry TD, et al. Electrocardiographic differentiation of early repolarization from subtle anterior ST-segment elevation myocardial infarction. Ann Emerg Med 2012; 60:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/58\">",
"      Ha&iuml;ssaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 2008; 358:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/59\">",
"      Tikkanen JT, Anttonen O, Junttila MJ, et al. Long-term outcome associated with early repolarization on electrocardiography. N Engl J Med 2009; 361:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/60\">",
"      Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/24/11658/abstract/61\">",
"      Shvilkin A, Bojovic B, Vajdic B, et al. Vectorcardiographic determinants of cardiac memory during normal ventricular activation and continuous ventricular pacing. Heart Rhythm 2009; 6:943.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2095 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11658=[""].join("\n");
var outline_f11_24_11658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22491416\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASIS OF INJURY CURRENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ECG-coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LOCALIZATION OF ISCHEMIA OR INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ST segment elevation/Q waves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Formation of Q waves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Criteria for abnormal Q waves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Anatomic correlates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Anterior and apical MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Inferior and right ventricular MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Posterior wall MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Multiple regions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Extent of the infarct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Identification of the infarct-related artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Inferior MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Anterior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Evolution in infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other ischemic ST-T patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Non-ST elevation (non-Q wave)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Coronary vasospasm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Stress-induced cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - LAD-T wave inversion pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Pseudonormalization of T waves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      LIMITATIONS IN THE DIAGNOSIS OF ISCHEMIA AND INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Potential underdiagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Fragmented QRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Potential overdiagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Distinction from acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Distinction from acute myocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Distinction from early repolarization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22491416\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2095\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2095|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/10/7339\" title=\"table 1\">",
"      ECG manifestations of acute myocardial ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/8/20619\" title=\"table 2\">",
"      ECG of prior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/27/11707\" title=\"table 3\">",
"      Causes and diagnosis of tall R waves in V1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/35/39483\" title=\"table 4\">",
"      Causes of ST segment elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/15/36091\" title=\"table 5\">",
"      Causes of Q waves on the electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2095|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/41/43674\" title=\"waveform 1\">",
"      ECG diffuse subendocardial ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/18/43306\" title=\"waveform 2A\">",
"      ECG in evolving anterior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/35/43578\" title=\"waveform 2B\">",
"      ECG late evolution of anterior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/21/43354\" title=\"waveform 3\">",
"      ECG acute inferior and right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/28/42442\" title=\"waveform 4\">",
"      ECG acute infero-postero-lateral myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/42/42666\" title=\"waveform 5\">",
"      ECG iof inferior MI with anterior ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/14/41194\" title=\"waveform 6\">",
"      Persistent ST segment elevation post-MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/42/43683\" title=\"waveform 7\">",
"      ECG LAD ischemia or infarct deep T-wave inversion pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/53/43866\" title=\"waveform 8\">",
"      ECG in pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?27/15/27892\" title=\"waveform 9\">",
"      ECG early repolarization tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?29/34/30255\" title=\"waveform 10\">",
"      ECG subarachnoid hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=related_link\">",
"      Clinical syndromes of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22689?source=related_link\">",
"      Differential diagnosis of basic electrocardiographic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/38/38505?source=related_link\">",
"      Early repolarization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=related_link\">",
"      Electrocardiogram in pericarditis and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4521?source=related_link\">",
"      Electrocardiogram in the prognosis of myocardial infarction or unstable angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=related_link\">",
"      Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36868?source=related_link\">",
"      Pathogenesis and diagnosis of Q waves on the electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_24_11659="Indications for delivery in preeclampsia PI";
var content_f11_24_11659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for delivery in preeclampsia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Maternal indications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gestational age greater than or equal to 37 weeks of gestation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Platelet count less than 100,000 cells per cubic millimeter",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Deteriorating liver function",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Progressive deterioration in renal function (eg, creatinine &gt;2 mg/dL, oliguria)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abruptio placentae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Persistent severe headaches or visual changes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Persistent severe epigastric pain, nausea, or vomiting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Fetal indications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe fetal growth restriction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nonreassuring results from fetal testing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oligohydramnios",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From the Working Group Report on High Blood Pressure in Pregnancy. National Institutes of Health, Washington, DC 2000. p. 19.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11659=[""].join("\n");
var outline_f11_24_11659=null;
var title_f11_24_11660="Preexposure eval HCW VZV";
var content_f11_24_11660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preexposure evaluation of health care workers for varicella vaccine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Obtain a history of varicella or zoster in the",
"employee. Employee is considered immune with a history of infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. If employee has a negative or uncertain history,",
"perform a serologic test. Employees with a positive serology should be",
"considered immune. Employees with a negative or indeterminate serology",
"should be considered for varicella vaccine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. If employee is pregnant, postpone administration of",
"varicella vaccine until after delivery and breastfeeding. If employee is",
"within 5 months of receipt of immunoglobulin preparation or blood or",
"plasma transfusion, postpone vaccination for at least 5 months after",
"the date of product administration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Before vaccination, assess employee for a vaccine",
"contraindication. If no contraindications present,",
"obtain informed consent and vaccinate. A booster vaccine should be",
"given 4-8 weeks later.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"1\">",
"        5. Current ACIP/CDC guidelines do not",
"specify the management of employees following immunization. We believe",
"the following are reasonable recommendations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"1\">",
"        a. If the employee does not develop any",
"rash, allow the employee to continue working through the entire",
"hospital (including with immunocompromised patients).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        b. If the employee develops a rash at the site of",
"injection, cover the lesions and allow the employee to continue working through the entire",
"hospital. Some institutions may wish to preclude working with",
"immunocompromised patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        c. If the employee develops a generalized",
"rash, furlough from hospital while lesions present. Consider",
"possibility that \"wild\" virus has caused varicella.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. If a vaccine contraindication is",
"present, reassess employee annually to see if contraindication no",
"longer present. If vaccine cannot be administered, advise employee",
"about the need to report to Occupational Health for any exposures to",
"varicella or zoster, or the development of skin lesions suggestive of",
"infection. Also advise employee about the availability of VZIG for",
"post-exposure prophylaxis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from the UNC Hospitals' Infection Control Policy Manual.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11660=[""].join("\n");
var outline_f11_24_11660=null;
var title_f11_24_11661="Fecundability in healthy couples";
var content_f11_24_11661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fecundability in a cohort of healthy couples attempting to conceive",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 280px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Zinaman, MJ, Clegg, ED, Brown, CC, et al. Estimates of human fertility and pregnancy loss. Fertil Steril 1996; 65:503.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11661=[""].join("\n");
var outline_f11_24_11661=null;
var title_f11_24_11662="Dialysis patients who received ICD devices";
var content_f11_24_11662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    The number of dialysis patients who received ICD devices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 292px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Number of patients receiving an implantable cardioverter-defibrillator (ICD) device by apparent secondary versus primary prevention. Annual counts of ICD implantations in US dialysis patients. Secondary prevention ascertained by the presence of at least one diagnosis for cardiac arrest or ventricular arrhythmia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Charytan DM, Patrick AR, Liu J, et al. Trends in the Use and Outcomes of Implantable Cardioverter-Defibrillators in Patients Undergoing Dialysis in the United States. Am J Kidney Dis 2011; 58:409. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11662=[""].join("\n");
var outline_f11_24_11662=null;
var title_f11_24_11663="Selecting IGRA or TST";
var content_f11_24_11663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 623px\">",
"   <div class=\"ttl\">",
"    Algorithm to guide choice of IGRA versus TST in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 603px; height: 534px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IGRA: interferon gamma release assay; TST: tuberculin skin test; BCG: Bacillus Calmette-Guerin vaccine.",
"     <br/>",
"     * Criteria A: high clinical suspicion for tuberculosis disease, and/or high risk for infection, progression, or poor outcome.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Criteria B: additional evidence needed to ensure adherence, and/or child healthy and at low risk.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_24_11663=[""].join("\n");
var outline_f11_24_11663=null;
